



**Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population based cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001185
Article Type:	Research
Date Submitted by the Author:	20-Mar-2012
Complete List of Authors:	Meidahl Petersen, Kasper; Rigshospitalet, University Hospital Copenhagen, Department of Clinical Pharmacology, Q Jimenez-Solem, Espen; Bispebjerg Hospital, Laboratory of Clinical Pharmacology Andersen, Jon Traerup; Bispebjerg Hospital, Department of Clinical Pharmacology Petersen, Morten; Bispebjerg Hospital, Department of Clinical Pharmacology Brødbæk, Kasper; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Poulsen, Henrik; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology Køber, Lars; Rigshospitalet, Department of Cardiology Torp-Pedersen, Christian; Gentofte Hospital, Department of Cardiology
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Evidence based practice
Keywords:	CLINICAL PHARMACOLOGY, Maternal medicine < OBSTETRICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study

**Kasper Meidahl Petersen MB<sup>1</sup>; Espen Jimenez-Solem MD<sup>1</sup>; Jon Trærup Andersen MD<sup>1</sup>;**

**Morten Petersen MD<sup>1</sup>, PhD; Kasper Brødbæk MD<sup>1</sup>; Henrik Enghusen Poulsen MD, DMSc<sup>1</sup>;**

**Lars Køber MD, DMSc<sup>2</sup>; Christian Torp-Petersen MD, DMSc<sup>3</sup>**

#### **Author affiliations**

1: Department of Clinical Pharmacology, Q, Rigshospitalet, University Hospital Copenhagen, Denmark

2: Department of Cardiology, Rigshospitalet, University Hospital Copenhagen, Denmark

3: Department of Cardiology, Gentofte Hospital, Gentofte, Denmark

**Keywords (MeSH):** Adrenergic beta-antagonists, pregnancy, small for gestational age infant, premature birth, perinatal mortality.

**Words:** 2995

#### **Correspondence to:**

Kasper Meidahl Petersen  
Department of Clinical Pharmacology, Q  
Rigshospitalet, University Hospital Copenhagen  
Tagensvej 20  
DK-2200 Copenhagen N  
Denmark  
Tel +45 5123 7716  
Fax +45 3545 2745  
E-mail: kaspermeidahl@gmail.com

**ABSTRACT**

**Objective:** To investigate the association between exposure to beta-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth, and perinatal mortality in a nationwide cohort.

**Design:** A population-based retrospective cohort study, using the Danish Fertility Database. We identified all pregnant women redeeming a prescription for beta-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes.

**Setting:** Register based survey.

**Participants:** 911685 births between 1995 and 2008 obtained from the Danish Fertility Database.

**Outcome measures:** Being born SGA was defined as having a birth weight below the tenth percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup> gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life, or stillbirth. Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks.

**Results:** We identified 2459 pregnancies exposed to beta-blockers. Beta-blocker exposure during pregnancy was found to be associated with increased risk of SGA; adjusted OR=1.97 (95% CI, 1.75–2.23), preterm birth; adjusted OR=2.26 (95% CI, 2.03–2.52) and perinatal mortality; adjusted OR=1.89 (95 % CI, 1.25–2.84). Analyses were adjusted for socio-economic and maternal variables. We found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other beta-blockers.

**Conclusion:** We found that exposure to beta-blockers during pregnancy was associated with being born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than

1  
2  
3  
4 other beta-blockers during pregnancy, and future treatment of pregnant women with beta-blockers  
5  
6 should therefore be based primarily on the individual needs of the mother and not the unborn child.  
7  
8

## 9 **ARTICLE SUMMARY**

### 10 **Article focus**

- 11 • There is contradictory evidence concerning the consequences of beta-blocker treatment  
12 during pregnancy.
- 13 • This survey explores the effects of beta-blocker exposure during pregnancy in a Danish birth  
14 cohort comprising all births in Denmark between 1995 and 2008. In addition we compared  
15 risks associated with exposure to labetalol with exposure to other beta-blockers.  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **Key messages**

- 25 • Redeeming prescriptions of beta-blockers was found to be significantly associated with  
26 increased risk of being born SGA, preterm birth, and perinatal mortality.
- 27 • We found comparable risk profiles in labetalol-exposed pregnancies and in pregnancies  
28 exposed to any other beta-blocker.  
29  
30  
31  
32  
33  
34  
35

### 36 **Strengths and limitations of this study**

- 37 • This study is the largest of its kind to date, and covers an entire nation which minimises risk  
38 of selection bias.
- 39 • Given the study design, we were not able to adjust for treatment indication and severity of  
40 maternal disease, nor were we able to rule out confounding by indication, the underlying  
41 maternal disease, as a possible explanation for our findings.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **INTRODUCTION**

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Beta-blockers are widely used in the treatment of chronic hypertension,[1-4] migraine,[5] essential  
5  
6 tremor[6], and various other conditions. There is contradictory evidence concerning the  
7  
8 consequences of beta-blocker treatment during pregnancy. Some studies report an association  
9  
10 between beta-blocker treatment and small for gestational age (SGA) newborns, and preterm  
11  
12 birth,[4,7-10] while others do not.[2,11] Preterm birth and being born SGA are both associated with  
13  
14 increased risk of perinatal mortality.[12,13] We set out to investigate whether the use of beta-  
15  
16 blockers during pregnancy was associated with being born SGA, preterm birth and perinatal  
17  
18 mortality in a nationwide survey between 1995 and 2008.  
19  
20  
21  
22  
23

## 24 **METHOD**

### 25 **Study population**

26  
27 We used data obtained from three nationwide registries: the Danish Fertility Database,[14] the  
28  
29 Danish National Hospital Register[15], and the National Prescription Register.[16] Data concerning  
30  
31 income and educational level were obtained respectively from the Income Statistics Register[17]  
32  
33 and the Danish Education register,[18] both of which are provided by Statistics Denmark. In  
34  
35 Denmark all citizens are given a unique ten-digit identification number at birth.[19] This number  
36  
37 can be used to link information between nationwide registers.  
38  
39  
40

41  
42 Using the Danish Fertility Database we identified 974 805 births between 1995 and 2008. We  
43  
44 removed 52 603 records lacking information on pregnancy duration and 7681 records with coding  
45  
46 errors. In addition, we excluded 2836 records with pregnancy-induced hypertension, defined as  
47  
48 having redeemed an antihypertensive drug prescription after the twentieth week of gestation, but  
49  
50 never before. The final study population thus comprised 911 685 births.  
51

52  
53 The Danish Fertility Database contains information on maternal age, date of birth, and  
54  
55 previous births, as well as on each child's sex, gestational age, weight, and mortality.[14]  
56  
57  
58  
59  
60

1  
2  
3  
4 Time of conception is based on ultrasound estimates in early pregnancy, or information on last  
5  
6 menstrual period.  
7

8 Information on redeemed prescriptions was retrieved from the National Prescription Register,  
9  
10 which holds information on date of redemption, quantity, strength, and form.[16] Drugs are coded  
11  
12 in accordance with the Anatomical Therapeutic Chemical (ATC) classification.  
13  
14

15 The Danish National Hospital Register contains information on diagnoses of somatic  
16  
17 admissions and outpatients at all Danish hospitals since 1977[15] in accordance with the Danish  
18  
19 revision of the 10th International Classification of Diseases (ICD)-system. Pre-eclampsia and  
20  
21 eclampsia were defined as women diagnosed with O13, O14, or O15. Migraine was defined as G43  
22  
23 or G44, essential tremor as G250 and arrhythmias as I47, I48, and I49. Maternal smoking was  
24  
25 defined as women diagnosed with UT00, UT20, UT21, UT22, and UT23.  
26  
27  
28  
29  
30

### 31 **Identification of Exposure**

32  
33 We defined exposure to beta-blockers as the redemption of at least two prescriptions between six  
34  
35 months before conception and the twentieth week of gestation. At least one of these prescriptions  
36  
37 had to be redeemed between conception and the twentieth week of gestation.  
38

39 We assessed exposure to beta-blockers by identifying redeemed prescriptions with ATC code C07.  
40  
41 Furthermore, we identified the most frequently redeemed beta-blockers in Denmark: labetalol  
42  
43 (C07AG01), metoprolol (C07AB02), atenolol (C07AB03), propranolol (C07AA05), pindolol  
44  
45 (C07AA03), and sotalol (C07AA07). Fewer than 50 pregnancies were exposed to any of the  
46  
47 remaining beta-blockers.  
48  
49

50 We divided beta-blocker exposure into exposure to labetalol and exposure to other beta-  
51  
52 blockers. The latter group was formed because there were few redeemed prescriptions of individual  
53  
54 beta-blockers other than labetalol. We compared risks associated with exposure to beta-blockers  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 with exposure to methyldopa (C02AB01, C02AB02), calcium channel blockers (C08C), and ACE  
5  
6 inhibitors (C09A) to assess possible confounding by indication.  
7

8  
9 Maternal diabetes mellitus was defined as redeeming a prescription for insulin or an insulin  
10  
11 analogue (ATC code A10A). Furthermore, we assessed co-medication with statins (ATC code C10)  
12  
13 and antiobesity drugs (ATC code A08A). We identified pregnant women redeeming prescriptions  
14  
15 with these drugs in order to adjust for diabetes mellitus, obesity, and statin use since these women  
16  
17 have different risk profiles for the defined outcomes.  
18  
19

## 20 21 22 **Definition of Outcomes**

23  
24 Being born SGA was defined as having a birth weight below the tenth percentile for the  
25  
26 corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup> gestational week.  
27  
28 Perinatal mortality was defined as either death occurring within the first 28 days of life, or stillbirth.  
29  
30 Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation,  
31  
32 but since then stillbirth is recorded for deaths after 22 gestational weeks.[20]  
33  
34  
35  
36  
37

## 38 **Statistical analyses**

39  
40 Data were managed and analysed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Logistic  
41  
42 regression models were developed for dichotomous variables adjusted for maternal age, year of  
43  
44 conception, annual household income, parity, and educational level (model 1). Maternal age was  
45  
46 divided into five groups: <20, 21-25, 26-30, 31-35, >35 years (no missing values). Annual  
47  
48 household income at year of birth was divided into quartiles (1266 missing values). Subjects were  
49  
50 divided into quartiles according to the number of previous births, including stillbirths (37 missing  
51  
52 values): 0, 1, 2, ≥3 births. Year of conception was ordered into three categories (1994-1998, 1999-  
53  
54 2003, and 2004-2008). Educational level was divided into tertiles by highest level of education  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 achieved at the year of birth. For missing information we used information from the following  
5  
6 calendar year (32 745 missing values).  
7

8  
9 We constructed a separate logistic regression model (model 2) including the socio-economic  
10 variables in model 1 and additional confounding variables: smoking status, co-medication (yes/no)  
11 with statins, antiobesity drugs, insulin and insulin analogues, and diagnoses of pre-  
12 eclampsia/eclampsia. These confounders were included in model 2 due to the high frequency of  
13 missing data, because information on smoking and diagnoses of pre-eclampsia/eclampsia were not  
14 available for the years 1995 and 2008. Maternal smoking was divided into four categories according  
15 to the number of cigarettes smoked daily (0, 1-10, 11-20, >20).  
16  
17  
18  
19  
20  
21  
22  
23

24 When estimating the risk of perinatal mortality, analyses were further adjusted for previous  
25 stillbirths. Odds ratios are presented with 95% confidence intervals (95% CIs). For description of  
26 basic characteristics we used frequencies with percentages. We used Chi-square tests to analyse  
27 differences in the proportions of the different classes of categorical baseline characteristics.  
28  
29  
30  
31  
32  
33 Statistical significance was defined as  $p < 0.05$ . All tests were two-sided.  
34

35 In addition, we carried out a propensity score-matched regression analysis to consolidate our  
36 findings. We calculated a propensity score for the likelihood of redeeming a beta-blocker during  
37 pregnancy by multivariate logistic regression conditional on baseline covariates. Using the Greedy  
38 matching macro (<http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas>), we  
39 matched each case to four controls on the basis of the propensity score (table 1). We did not match  
40 on diagnoses of pre-eclampsia/eclampsia since a large fraction of these cases redeemed beta-blocker  
41 prescriptions.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

## 53 RESULTS

54  
55  
56  
57  
58  
59  
60



Table 1 presents maternal characteristics in beta-blocker-exposed and unexposed women (number and percentage of pregnancies). We identified 2381 pregnancies exposed to only one beta-blocker, 1452 exposed to labetalol only, and 929 exposed to other beta-blockers. 98 pregnancies were exposed to more than one beta-blocker. We found 515 pregnancies exposed to methyldopa, 86 pregnancies to calcium channel blockers (CCBs), and 48 pregnancies exposed to ACE inhibitors. Women exposed to beta-blockers during pregnancy were older, had higher income, and higher parity than unexposed women. The proportions of women redeeming prescriptions for statins, antiobesity preparations, and insulins were higher among the beta-blocker-exposed group. The proportion of pregnancies complicated by pre-eclampsia was higher among beta-blocker-exposed pregnancies. There was no difference in smoking prevalence between beta-blocker-exposed and unexposed women (table 1).

	Beta-blocker-exposed	Beta-blocker-unexposed	Propensity matched
<b>Table 1.</b> Basic characteristics for pregnancies exposed to beta-blockers, compared with unexposed pregnancies and propensity score-matched pregnancies.			
	(n=2459)	(n=909228)	(n=9662)

Characteristics	n (%)	n (%)	p-value <sup>a</sup>	n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001		0.991
Low	739 (30.05)	311 600 (35.45)		2965 (30.69)	
Medium	972 (39.53)	285 450 (32.47)		3883 (40.19)	
High	707 (28.75)	279 431 (31.79)		2814 (29.12)	
<b>Annual household income (GBP)</b>			<0.001		0.989
0- 36 770	509 (23.99)	226 228 (24.84)		1924 (19.91)	
36 771 – 52 703	594 (24.16)	227 195 (24.96)		2337 (24.19)	
52 704 – 74 699	662 (26.92)	227 089 (24.94)		2631 (27.23)	
≥ 74 700	693 (28.18)	227 448 (24.98)		2770 (28.67)	
<b>Parity</b>			<0.001		0.998
1	900 (36.60)	394 661 (43.29)		3487 (28.87)	
2	918 (37.33)	338 989 (37.18)		3658 (30.28)	
3	455 (18.50)	129 482 (14.20)		1788 (14.80)	
>3	186 (7.56)	46 057 (5.05)		729 (6.04)	
<b>Age (years)</b>			<0.001		1.000
<20	18 (0.73)	26 321 (2.89)		68 (0.56)	
21-25	174 (7.07)	147 298 (16.16)		699 (5.79)	
26-30	700 (28.47)	350 105 (38.40)		2757 (22.82)	
31-35	930 (37.82)	281 154 (30.84)		3665 (30.34)	
>35	637 (24.90)	104 339 (11.44)		2473 (20.47)	
<b>Daily cigarettes<sup>b</sup></b>			0.427		0.385
0	1548 (80.29)	572 642 (81.15)		6140 (81.81)	
1-10	251 (13.02)	90 033 (12.76)		913 (12.16)	
11-20	114 (5.19)	36201 (5.13)		394 (5.25)	
>20	15 (0.78)	4849 (0.69)		59 (0.79)	
<b>Statins</b>			<0.001		0.492
Used	5 (0.20)	111 (0.01)		14 (0.14)	
Not used	2454 (99.8)	909 115 (99.99)		9648 (99.86)	
<b>Antiobesity preparations (A10)</b>			0.018		0.251
Used	9 (0.40)	1539 (0.17)		23 (0.24)	
Not used	2450 (99.6)	907 687 (99.83)		9639 (99.76)	
<b>Insulins and analogues</b>			<0.001		0.782
Used	101 (4.11)	4208 (0.46)		412 (4.14)	
Not used	2358 (95.89)	905 018 (99.53)		9250 (95.74)	
<b>Pre-eclampsia (O13-O15)</b>			<0.001		-
Yes	99 (4.03)	7806 (0.86)		-	
No	2360 (95.97)	901 420 (99.14)		-	

<sup>a</sup>Chi-square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

Women redeeming labetalol prescriptions were older, had a higher education level, and a higher prevalence of preeclampsia and smoking than women exposed to other beta-blockers (table 2). The proportion of women redeeming prescriptions for insulin was larger among the labetalol-exposed group. There was no difference in income or co-medication with statins and antiobesity preparations between the two groups. Diagnoses of migraine and arrhythmias were more common among women exposed to any other beta-blocker. Women exposed to other beta-blockers had higher parity than those exposed to labetalol.

**Table 2.** Basic characteristics for pregnancies exposed to labetalol, compared with pregnancies exposed to other beta-blockers.

Characteristics	Labetalol (n=1452) n (%)	Other beta-blockers (n=929) n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001
Low	391 (26.93)	321 (34.55)	
Medium	571 (39.33)	369 (39.72)	
High	462 (31.82)	226 (24.33)	
<b>Annual household income (GBP)</b>			0.138
0 – 36 770	202 (13.91)	289 (31.11)	
36 771 – 52 703	223 (15.36)	357 (38.43)	
52 704 – 74 699	228 (15.70)	413 (44.46)	
≥74 700	275 (19.94)	393 (42.30)	
<b>Parity</b>			0.004
0	512 (35.26)	363 (39.07)	
1	586 (40.36)	308 (33.15)	
2	256 (17.63)	179 (19.27)	
≥3	98 (6.75)	79 (8.50)	
<b>Age (years)</b>			<0.001
<20	7 (0.58)	10 (1.08)	
21-25	69 (4.75)	97 (10.44)	
26-30	406 (27.96)	275 (29.60)	
31-35	586 (40.36)	314 (33.79)	
>35	384 (26.45)	233 (25.08)	
<b>Daily cigarettes<sup>b</sup></b>			<0.001
0	933 (64.26)	565 (60.82)	
1-10	130 (8.95)	112 (12.06)	
11-20	44 (3.03)	62 (6.67)	

>20	9 (6.19)	6 (0.65)	
<b>Antiobesity drugs</b>			0.052
Yes	5 (0.34)	9 (0.97)	
No	1447 (99.66)	920 (99.03)	
<b>Statins</b>			0.261
Yes	5 (0.34)	1 (0.10)	
No	1447 (99.66)	928 (99.90)	
<b>Insulins and analogues</b>			<0.001
Yes	1369 (5.72)	16 (1.72)	
No	83 (94.28)	913 (92.28)	
<b>Migraine</b>			<0.001
Yes	26 (1.79)	46 (4.95)	
No	1426 (98.21)	883 (95.05)	
<b>Pre-eclampsia</b>			0.001
Yes	1378 (94.90)	908 (97.84)	
No	74 (5.10)	21 (2.26)	
<b>Arrhythmia</b>			<0.001
Yes	23 (1.58)	82 (8.83)	
No	1429 (98.42)	847 (91.17)	
<b>Essential tremor</b>			0.030
Yes	-	3 (0.33)	
No	1452 (100)	926 (99.67)	

<sup>a</sup>Chi square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

Table 3 presents ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure to beta-blockers during pregnancy.

### SGA

We found 93 662 children born SGA in the unexposed population (table 3). There were 446 children born SGA among pregnancies exposed to some kind of beta-blocker. We found a higher proportion of SGA among women exposed to beta-blockers compared with unexposed women.

1  
2  
3  
4 Women exposed to labetalol or to other beta-blockers had similarly higher odds ratios than  
5  
6 unexposed women (table 3).  
7  
8  
9

### 10 11 **Preterm birth**

12  
13 We identified 109 163 preterm births in the unexposed population (table 3). There were 697 preterm  
14  
15 births among pregnancies exposed to beta-blockers. We found an association between preterm birth  
16  
17 and beta-blocker exposure compared with unexposed women. Those exposed to labetalol or to other  
18  
19 beta-blockers had similarly higher odds ratios than unexposed women (table 3).  
20  
21  
22  
23

### 24 25 **Perinatal mortality**

26  
27 We identified 6048 perinatal deaths in the unexposed population (table 3). There were 44 perinatal  
28  
29 deaths among infants exposed to beta-blockers. We found a higher rate of perinatal mortality  
30  
31 amongst women exposed to beta-blockers (table 3).  
32

33  
34 When stratifying for different beta-blockers we found 30 perinatal deaths among labetalol-  
35  
36 exposed pregnancies. Labetalol exposure was associated with increased risk of perinatal mortality  
37  
38 (table 3).  
39

40  
41 We identified 13 perinatal deaths among pregnancies exposed to other beta-blockers.  
42  
43 Exposure to other beta-blockers was found to be significantly associated with perinatal mortality in  
44  
45 the unadjusted model and model 1. However, adjusting our analysis for additional confounding  
46  
47 variables (Model 2) rendered the association statistically insignificant (table 3).  
48  
49  
50

### 51 52 **Other analyses**

53  
54 We identified 515 pregnancies exposed to methyl dopa (table 3). We found 61 children born SGA,  
55  
56 216 preterm births and 4 perinatal deaths among these pregnancies. We found a positive association  
57  
58  
59  
60

between children born SGA and exposure to methyldopa, and between methyldopa exposure and increased risk of preterm birth. Exposure to methyldopa during pregnancy was not significantly associated with perinatal mortality (table 3).

**Table 3.** ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure to beta-blockers during pregnancy.

Exposure	N (%)	Crude OR (95% CI)	Adjusted (model 1) OR (95% CI)	Adjusted (model 2) OR (95% CI)
SGA				
Unexposed (n=909 226)	93 662 (10.30)	Reference	Reference	Reference
All beta-blockers (n=2459)	446 (18.14)	1.93 (1.74-2.14)	1.99 (1.79-2.21)	1.97 (1.75-2.23)
Labetalol only (n=1452)	258 (17.77)	1.88 (1.64-2.15)	1.95 (1.70-2.24)	2.02 (1.72-2.37)
Other beta-blockers (n=929)	179 (19.27)	2.08 (1.76-2.44)	2.11 (1.79-2.49)	2.01 (1.66-2.43)
Methyldopa (n= 515)	61 (11.84)	1.17 (0.89-1.53)	1.32 (1.01-1.73)	1.43 (1.04-1.96)
CCBs (n=86)	21 (24.42)	2.30 (1.42-3.73)	2.24 (1.36-3.67)	1.88 (1.02-3.49)
Preterm birth				
Unexposed (n=909 226)	109 163 (12.01)	Reference	Reference	Reference
All beta-blockers (n=2459)	697 (28.34)	2.9 (2.66-3.14)	2.71 (2.48-2.97)	2.26 (2.03-2.52)
Labetalol only (n=1452)	473 (32.58)	3.54 (3.17-3.95)	3.33 (2.98-3.72)	2.74 (2.39-3.13)
Other beta-blockers (n=929)	206 (22.17)	2.08 (1.78-2.43)	1.93 (1.65-2.26)	1.69 (1.41-2.03)
Methyldopa (n= 515)	216 (41.94)	5.29 (4.44-6.31)	5.03 (4.21-6.01)	4.21 (3.38-5.23)
CCBs (n=86)	26 (30.23)	2.55 (1.63-3.99)	2.50 (1.60-3.89)	2.15 (1.26-3.67)
Perinatal mortality				
Unexposed (n=909 226)	6048 (0.67)	Reference	Reference	Reference
All beta-blockers (n=2459)	44 (1.79)	2.72 (2.02-3.67)	2.69 (1.98-3.65)	1.89 (1.25-2.84)
Labetalol only (n=1452)	30 (2.07)	3.15 (2.19-4.52)	3.24 (2.25-4.67)	2.08 (1.26-3.44)
Other beta-blockers (n=929)	13 (1.39)	2.12 (1.22-3.66)	1.92 (1.08-3.40)	1.72 (0.85-3.48)
Methyldopa (n= 515)	4 (0.78)	1.15 (0.43-3.07)	1.16 (0.43-3.12)	0.35 (0.05-2.50)
CCBs (n=86)	1 (1.16)	1.78 (0.25-12.57)	2.00 (0.28-14.83)	3.26 (0.45-23.77)

Analyses are adjusted for maternal age, household income, educational level, parity, birth year and prior stillbirths.  
<sup>a</sup>Model 2 is furthermore adjusted for smoking and comedication with statins, antiobesity preparations, insulins and diagnoses of pre-eclampsia/eclampsia. The cohort in model 2 comprises all births between 1996 and 2007 (n=778 394).

1  
2  
3  
4 We found 86 pregnancies exposed to calcium channel blockers (table 3). These included 17  
5  
6 children born SGA, 18 preterm births and 1 perinatal death. We found an association between  
7  
8 exposure to calcium channel blockers and children born SGA in all models.  
9

10 Additionally, we found an association between exposure to calcium channel blockers and  
11  
12 increased risk of preterm birth in all models. As with methyldopa, exposure to calcium channel  
13  
14 blockers during pregnancy was not found to be associated with perinatal mortality (table 3).

15 Analyses for exposure to ACE inhibitors were not performed since we identified only 48  
16  
17 pregnancies exposed to them.  
18  
19

20  
21 Post hoc we analysed the effect of exposure to all beta-blockers using a propensity score-  
22  
23 matched control group (Table 1) and found similar results to those of the primary analyses: SGA,  
24  
25 OR=1.93 (95% CI, 1.71–2.19); preterm birth, OR=2.40 (95% CI, 2.16–2.67); perinatal mortality,  
26  
27 OR=3.22 (95% CI, 2.15–4.82).  
28  
29  
30  
31

## 32 **DISCUSSION**

33  
34 In the present study, which we believe to be the largest of its kind to date, we found an association  
35  
36 between redeeming prescriptions of beta-blockers during pregnancy and being born SGA, preterm  
37  
38 birth, and perinatal mortality. In addition, we found an association between redeeming prescriptions  
39  
40 of methyldopa and calcium channel blockers, being born SGA, and preterm birth. Methyldopa and  
41  
42 calcium channel blockers were not found to be associated with perinatal mortality.  
43  
44

45  
46 We found exposure to any beta-blocker to be associated with being born SGA. Our results are  
47  
48 in accordance with a recent study reporting increased risk of being born SGA among pregnancies  
49  
50 exposed to selective beta-blockers (OR=6.00; 95% CI, 1.06–33.87) and labetalol (OR=2.26; 95%  
51  
52 CI, 1.04–4.88).[9] Labetalol is generally considered safe for use during pregnancy.[1,8,21]  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Exposure to beta-blockers was found to be associated with preterm birth. When stratifying for  
5  
6 different beta-blockers we found an increased risk of preterm birth after exposure to labetalol, and  
7  
8 all other beta-blockers, respectively.  
9

10 We found an association between exposure to beta-blockers and perinatal mortality. When  
11  
12 stratifying for different beta-blockers we found this association to be statistically significant for  
13  
14 exposure to labetalol and other beta-blockers. When adjusting our analysis for maternal co-  
15  
16 morbidity, co-medication, and smoking, only labetalol was found to be associated with perinatal  
17  
18 mortality.  
19  
20

21 Methyldopa is mainly used to treat chronic hypertension during pregnancy as first-line  
22  
23 therapy.[1] Previous studies did not find any associations between methyldopa exposure and being  
24  
25 born SGA or preterm birth.[1,3] Methyldopa has not been found to have effects on placental  
26  
27 haemodynamics.[1] However, a recent case-control study reported an increased risk of being born  
28  
29 SGA among pregnancies exposed to centrally acting adrenergic agents during the second and third  
30  
31 trimesters[9]: OR=1.70 (95% CI, 1.00–2.89). We found that methyldopa exposure was associated  
32  
33 with being born SGA and preterm birth. This could be due to indicative antihypertensive treatment  
34  
35 with methyldopa in pregnant women with diabetes or pregnancy related diabetes. The prevalence of  
36  
37 diabetes among methyldopa-exposed pregnancies was found to be higher: 11.1% compared with  
38  
39 3.9% among beta-blocker-exposed pregnancies. Increased risk of preterm birth was still seen after  
40  
41 adjusting our analyses for additional confounding variables in model 2. We found no association  
42  
43 between exposure to methyldopa and perinatal mortality. These findings are consistent with those of  
44  
45 a previous study.[3]  
46  
47  
48  
49

50 Calcium channel blockers are considered to be safe during pregnancy.[3,22] We found that  
51  
52 exposure to calcium channel blockers was associated with being born SGA and with preterm birth.  
53  
54 The risk of being born SGA and preterm of birth remained after adjusting our analyses for  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 additional confounding variables in model 2. We found no statistically significant association  
5  
6 between calcium channel blocker exposure during pregnancy and perinatal mortality.  
7

8  
9 We chose to analyse two outcomes previously reported to be associated with beta-blocker  
10 exposure during pregnancy —SGA and preterm birth[1,10,23] — that have been associated with  
11 increased perinatal mortality in previous studies.[12,13] Therefore we investigated the risk of  
12 perinatal mortality among beta-blocker-exposed pregnancies. We compared risks associated with  
13 exposure to beta-blockers with exposure to methyldopa and calcium channel blockers to assess  
14 possible confounding by indication. Our analyses show a similar risk of being born SGA and an  
15 increased risk of preterm birth for all recommended agents during pregnancy. There are various  
16 possible explanations for this finding. It is possible that the underlying indication for treatment,  
17 maternal disease, is the true risk factor. Possible maternal diseases include hypertension, either  
18 predating or complicating pregnancy. Accordingly, we were not able to rule out a potential effect of  
19 maternal disease on perinatal outcomes.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 We found an association between exposure to beta-blockers during pregnancy and perinatal  
34 mortality. This association was not found for exposure to methyldopa and calcium channel  
35 blockers, which might be due to the small number of cases.  
36  
37  
38

39 We believe that the similar risks found for exposure to the various beta-blockers and SGA,  
40 preterm birth, and perinatal mortality are a class effect. This seems to be true in spite of statistically  
41 significant differences in the basic characteristics of women exposed to labetalol and those exposed  
42 to other beta-blockers (table 2). After adjustments were made for these variables, we found  
43 comparable risk profiles for labetalol-exposed pregnancies and pregnancies exposed to other beta-  
44 blockers. Most beta-blockers are known to cross the placenta,[21,24] and effects on placental  
45 haemodynamics have been observed in both human and animal studies. A mechanism has been  
46 proposed of diminished placental blood flow due to the selective vasoconstriction of placental  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 vessels by beta-blockers without intrinsic sympathomimetic activity.[24] This effect on placental  
5  
6 haemodynamics could explain growth retardation of foetuses exposed to beta-blockers during  
7  
8 pregnancy and might result in children being born SGA and preterm.  
9

10  
11 We defined exposure as redemption of at least two prescriptions between six months before  
12  
13 conception and the twentieth week of gestation. At least one of these prescriptions had to be  
14  
15 redeemed between conception and twentieth week of gestation. We believe that this model  
16  
17 increases the probability of identifying continuous use that extends into pregnancy.  
18

19  
20 The rate of perinatal mortality in Denmark is low (table 3).[25] A large number of women  
21  
22 exposed to beta-blockers, methyldopa, and calcium channel blockers are therefore needed to  
23  
24 identify a possible risk increase associated with these outcomes. Our cohort comprises all births in  
25  
26 Denmark between 1995 and 2008. This minimises confounding due to race, educational level, and  
27  
28 other socio-economic factors. The national Danish registers cover the entire nation and are  
29  
30 considered valid. As part of the national health care reimbursement scheme, Danish pharmacies are  
31  
32 required by law to register all redeemed prescriptions. Approximately 97.5% of all redeemed  
33  
34 prescriptions are registered in the Danish Prescription register.[16] Our study includes data on  
35  
36 exposure to beta-blockers based on information on prescriptions paid for at the pharmacy, and not  
37  
38 only prescribed by the physician, thereby increasing the probability of exposure. Furthermore, our  
39  
40 study was not confounded by recall bias since information was recorded prospectively. The Danish  
41  
42 Fertility Database contains more than 99% of all births during the study period.[14]  
43  
44

45  
46 Limitations of our study include missing information on maternal weight and alcohol  
47  
48 consumption. We were unable to adjust for treatment indication and severity of maternal disease.  
49  
50 Given the study design, we were not able to address this issue further, nor were we able to rule out  
51  
52 confounding by indication, the underlying maternal disease, as a possible explanation for our  
53  
54 findings.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 We estimated exposure from National Prescription Registry data, which contains information  
5  
6 on all redeemed prescriptions.[16] Overestimation of exposure is therefore a possibility, since we  
7  
8 cannot adjust for a potential lack of compliance. However, in a study by Olesen et al. conducted in a  
9  
10 cohort of pregnant Danish women in the county of North Jutland,[26] compliance with prescribed  
11  
12 beta-blockers was estimated to be complete, strengthening the validity of our analyses.  
13  
14 Furthermore, overestimation of exposure would bias the estimates towards unity.  
15  
16

17  
18 There is a general consensus that labetalol is safer than other beta-blockers during pregnancy  
19  
20 and this drug is rapidly becoming the first-line choice in conditions such as chronic hypertension  
21  
22 during pregnancy.[21,23] We found an association between redeeming prescriptions for beta-  
23  
24 blockers and being born SGA, preterm birth, and perinatal mortality. Risk profiles for pregnancies  
25  
26 exposed to labetalol and to other beta-blockers were similar. Our findings therefore suggest that  
27  
28 future treatment of pregnant women with beta-blockers should be based primarily on the individual  
29  
30 needs of the mother and not of the unborn child. The increasing use and uncertainty of effects and  
31  
32 possible side effects of treatment with beta-blockers during pregnancy call for further studies.  
33  
34  
35  
36

### 37 **Conflicts of interests**

38  
39 The authors have no relevant conflict of interests.  
40  
41

### 42 **Funding**

43  
44 The project was sponsored by the Capital Region of Copenhagen.  
45  
46

### 47 **Contributorship Statement**

48  
49 KMP, EJS, JTA, MP, KB, LK, CTP, HEP

50 KMP, EJS, JTA and HEP conceptualized the study. MP, KB, LK and CTP assisted with the study  
51  
52 design. KMP performed the analyses assisted by EJS and JTA, MP, KB, LK, CTP and HEP assisted  
53  
54 in the interpretation. KMP, EJS, JTA, MP, KB, LK, CTP and HEP wrote and revised the final  
55  
56 manuscript. Figure design was done by KMP, EJS, JTA, MP, KB, LK, CTP and HEP. All authors  
57  
58 approved the final version to be published.  
59  
60

## REFERENCES

- 1 Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996 Jul 25;335(4):257-65.
- 2 Magee LA, Ornstein MP, von DP. Fortnightly review: management of hypertension in pregnancy. BMJ 1999 May 15;318(7194):1332-6.
- 3 Afifi Y, Churchill D. Pharmacological treatment of hypertension in pregnancy. Curr Pharm Des 2003;9(21):1745-53.
- 4 Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003;(3):CD002863.
- 5 Modi S FAU - Lowder D, Lowder DM. Medications for migraine prophylaxis.(0002-838X (Print)).
- 6 Lyons KE FAU - Pahwa R, Pahwa R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.(1172-7047 (Print)).
- 7 Sibai BM, Gonzalez AR, Mabie WC et al. comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987 Sep;70(3 Pt 1):323-7.
- 8 Magee LA, Elran E, Bull SB et al. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000 Jan;88(1):15-26.

- 1  
2  
3  
4 9 Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and  
5  
6 the risk of major congenital malformations or small-for-gestational-age newborns. *Birth*  
7  
8 *Defects Res B Dev Reprod Toxicol* 2010 Apr;89(2):147-54.  
9
- 10  
11 10 Lydakis C, Lip GY, Beevers M et al. Atenolol and foetal growth in pregnancies complicated  
12  
13 by hypertension. *Am J Hypertens* 1999 Jun;12(6):541-7.  
14  
15
- 16  
17 11 Abalos E, Duley L, Steyn DW et al. Antihypertensive drug therapy for mild to moderate  
18  
19 hypertension during pregnancy. *Cochrane Database Syst Rev* 2007;(1):CD002252.  
20  
21
- 22  
23 12 Zeitlin J, El AM, Jarreau PH et al. Impact of foetal growth restriction on mortality and  
24  
25 morbidity in a very preterm birth cohort. *J Pediatr* 2010 Nov;157(5):733-9.  
26  
27
- 28  
29 13 Challis JR, Lye SJ, Gibb W et al. Understanding preterm labor. *Ann N Y Acad Sci* 2001  
30  
31 Sep;943:225-34.  
32
- 33  
34 14 Knudsen LB. The Danish Fertility Database. *Dan Med Bull* 1998 Apr;45(2):221-5.  
35  
36
- 37  
38 15 Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A  
39  
40 valuable source of data for modern health sciences. *Dan Med Bull* 1999 Jun;46(3):263-8.  
41
- 42  
43 16 Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. *Dan Med Bull* 1997  
44  
45 Sep;44(4):445-8.  
46
- 47  
48 17 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments.  
49  
50 *Scand J Public Health* 2011 Jul;39(7 Suppl):103-5.  
51
- 52  
53 18 Jensen VM, Rasmussen AW. Danish education registers. *Scand J Public Health* 2011  
54  
55 Jul;39(7 Suppl):91-4.  
56  
57  
58  
59  
60

- 1  
2  
3  
4 19 Pedersen CB, Gotzsche H, Moller JO et al. The Danish Civil Registration System. A cohort  
5 of eight million persons. *Dan Med Bull* 2006 Nov;53(4):441-9.  
6  
7  
8  
9  
10 20 Knudsen LB, Borlum KF. Monitoring perinatal mortality and perinatal care with a national  
11 register: content and usage of the Danish Medical Birth Register. *Community Med* 1986  
12 Feb;8(1):29-36.  
13  
14  
15  
16  
17 21 Karthikeyan VJ, Lip GY. Hypertension in pregnancy: pathophysiology and management  
18 strategies. *Curr Pharm Des* 2007;13(25):2567-79.  
19  
20  
21  
22 22 Magee LA, Schick B, Donnenfeld AE et al. The safety of calcium channel blockers in  
23 human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol* 1996  
24 Mar;174(3):823-8.  
25  
26  
27  
28  
29  
30 23 Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy.  
31 *Hypertension* 2008 Apr;51(4):960-9.  
32  
33  
34  
35  
36 24 Lennestal R, Otterblad OP, Kallen B. Maternal use of antihypertensive drugs in early  
37 pregnancy and delivery outcome, notably the presence of congenital heart defects in the  
38 infants. *Eur J Clin Pharmacol* 2009 Jun;65(6):615-25.  
39  
40  
41  
42  
43 25 World Health Organization. Levels & Trends in Child Mortality. Report 2011. Estimates  
44 Developed by the UN Inter-agency for Child Mortality Estimation. 2011.  
45  
46  
47 [http://www.who.int/child\\_adolescent\\_health/documents/child/childmortality\\_booklet\\_2011.](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf)  
48 [pdf](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf), World Health Organization.  
49  
50  
51

52 Ref Type: Online Source  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 26 Olesen C, Sondergaard C, Thrane N et al. Do pregnant women report use of dispensed  
5  
6 medications? Epidemiology 2001 Sep;12(5):497-501.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population based cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001185.R1
Article Type:	Research
Date Submitted by the Author:	26-Jun-2012
Complete List of Authors:	Meidahl Petersen, Kasper; Rigshospitalet, University Hospital Copenhagen, Department of Clinical Pharmacology, Q Jimenez-Solem, Espen; Bispebjerg Hospital, Laboratory of Clinical Pharmacology Andersen, Jon Traerup; Bispebjerg Hospital, Department of Clinical Pharmacology Petersen, Morten; Bispebjerg Hospital, Department of Clinical Pharmacology Brødbæk, Kasper; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology K♦ber, Lars; Rigshospitalet, Department of Cardiology Torp-Pedersen, Christian; Gentofte Hospital, Department of Cardiology Poulsen, Henrik; Bispebjerg Hospital, Department of Clinical Pharmacology; Rigshospitalet, Laboratory of Clinical Pharmacology
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Evidence based practice, Reproductive medicine, obstetrics and gynaecology
Keywords:	CLINICAL PHARMACOLOGY, Maternal medicine < OBSTETRICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts



1  
2  
3  
4 1 Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide  
5 2 population-based cohort study  
6  
7 3  
8

9 4 **Kasper Meidahl Petersen MB<sup>1</sup>; Espen Jimenez-Solem MD<sup>1</sup>; Jon Trærup Andersen MD<sup>1</sup>;**  
10  
11 5 **Morten Petersen MD<sup>1</sup>, PhD; Kasper Brødbæk MD<sup>1</sup>; Lars Køber MD, DMSc<sup>2</sup>; Christian**  
12  
13 6 **Torp-Petersen MD, DMSc<sup>3</sup>; Henrik Enghusen Poulsen MD, DMSc<sup>1</sup>**  
14  
15  
16  
17

18 8 **Author affiliations**

19  
20 9 1: Department of Clinical Pharmacology, Q, Rigshospitalet, University Hospital Copenhagen,  
21  
22 10 Denmark  
23

24 11 2: Department of Cardiology, Rigshospitalet, University Hospital Copenhagen, Denmark  
25

26 12 3: Department of Cardiology, Gentofte Hospital, Gentofte, Denmark  
27  
28

29 13  
30  
31 14 **Keywords (MeSH):** Adrenergic beta-antagonists, pregnancy, small for gestational age infant,  
32 15 premature birth, perinatal mortality.  
33

34 16 **Words:** 3054  
35  
36

37 17  
38 18 **Correspondence to:**

39 19 Kasper Meidahl Petersen  
40 20 Department of Clinical Pharmacology, Q  
41 21 Rigshospitalet, University Hospital Copenhagen  
42 22 Tagensvej 20  
43 23 DK-2200 Copenhagen N  
44 24 Denmark  
45 25 Tel +45 5123 7716  
46 26 Fax +45 3545 2745  
47 27 E-mail: kaspermeidahl@gmail.com  
48  
49 28

50  
51 29  
52

53 30  
54

55 31  
56  
57  
58  
59  
60

1  
2  
3  
4 15  
6 2 **ABSTRACT**

7  
8 3 **Objective:** To investigate the association between exposure to beta-blockers during pregnancy and  
9  
10 4 the risk of being born small for gestational age (SGA), preterm birth, and perinatal mortality in  
11  
12 5 a nationwide cohort.

13  
14 6 **Design:** A population-based retrospective cohort study, using the Danish Fertility Database. We  
15  
16 7 identified all pregnant women redeeming a prescription for beta-blockers using the National  
17  
18 8 Prescription Registry. Multivariate logistic regression models were used to assess the association  
19  
20 9 between exposure and our outcomes.

21  
22 10 **Setting:** Register based survey.

23  
24 11 **Participants:** 911685 births between 1995 and 2008 obtained from the Danish Fertility Database.

25  
26 12 **Outcome measures:** Being born SGA was defined as having a birth weight below the tenth  
27  
28 13 percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup>  
29  
30 14 gestational week. Perinatal mortality was defined as either death occurring within the first 28 days  
31  
32 15 of life, or stillbirth. Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28  
33  
34 16 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks.

35  
36 17 **Results:** We identified 2459 pregnancies exposed to beta-blockers. Beta-blocker exposure during  
37  
38 18 pregnancy was found to be associated with increased risk of SGA; adjusted OR=1.97 (95% CI,  
39  
40 19 1.75–2.23), preterm birth; adjusted OR=2.26 (95% CI, 2.03–2.52) and perinatal mortality; adjusted  
41  
42 20 OR=1.89 (95 % CI, 1.25–2.84). Analyses were adjusted for socio-economic and maternal variables.  
43  
44 21 We found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to  
45  
46 22 other beta-blockers.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Conclusion:** We found that exposure to beta-blockers during pregnancy was associated with being  
2 born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than  
3 other beta-blockers during pregnancy..

## 4 **ARTICLE SUMMARY**

### 5 **Article focus**

- 6 • There is contradictory evidence concerning the consequences of beta-blocker treatment  
7 during pregnancy.
- 8 • This survey explores the effects of beta-blocker exposure during pregnancy in a Danish birth  
9 cohort comprising all births in Denmark between 1995 and 2008. In addition we compared  
10 risks associated with exposure to labetalol with exposure to other beta-blockers.

### 11 **Key messages**

- 12 • Redeeming prescriptions of beta-blockers was found to be significantly associated with  
13 increased risk of being born SGA, preterm birth, and perinatal mortality.
- 14 • We found comparable risk profiles in labetalol-exposed pregnancies and in pregnancies  
15 exposed to any other beta-blocker.

### 16 **Strengths and limitations of this study**

- 17 • This study is the largest of its kind to date, and covers an entire nation which minimises risk  
18 of selection bias.
- 19 • Given the study design, we were not able to adjust for treatment indication and severity of  
20 maternal disease, nor were we able to rule out confounding by indication, the underlying  
21 maternal disease, as a possible explanation for our findings.

## 23 **INTRODUCTION**

1  
2  
3  
4 1 Beta-blockers are widely used in the treatment of chronic hypertension,[1-4] migraine,[5] essential  
5  
6 2 tremor[6], and various other conditions. There is contradictory evidence concerning the  
7  
8 3 consequences of beta-blocker treatment during pregnancy. Some studies report an association  
9  
10 4 between beta-blocker treatment and small for gestational age (SGA) newborns, and preterm  
11  
12 5 birth,[4,7-10] while others do not.[2,11] Preterm birth and being born SGA are both associated with  
13  
14 6 increased risk of perinatal mortality.[12,13] We set out to investigate whether the use of beta-  
15  
16 7 blockers during pregnancy was associated with being born SGA, preterm birth and perinatal  
17  
18 8 mortality in a nationwide survey between 1995 and 2008.  
19  
20  
21  
22  
23

## 24 **METHOD**

### 25 **Study population**

26  
27  
28 12 We used data obtained from three nationwide registries: the Danish Fertility Database,[14] the  
29  
30 13 Danish National Hospital Register[15], and the National Prescription Register.[16] Data concerning  
31  
32 14 income and educational level were obtained respectively from the Income Statistics Register[17]  
33  
34 15 and the Danish Education register,[18] both of which are provided by Statistics Denmark. In  
35  
36 16 Denmark all citizens are given a unique ten-digit identification number at birth.[19] This number  
37  
38 17 can be used to link information between nationwide registers.  
39  
40  
41

42 18 Using the Danish Fertility Database we identified 974 805 births between 1995 and 2008. We  
43  
44 19 removed 52 603 records lacking information on pregnancy duration and 7681 records with coding  
45  
46 20 errors. In addition, we excluded 2836 records with pregnancy-induced hypertension, defined as  
47  
48 21 having redeemed an antihypertensive drug prescription after the twentieth week of gestation, but  
49  
50 22 never before. The final study population thus comprised 911 685 births.  
51  
52

53 23 The Danish Fertility Database contains information on maternal age, date of birth, and  
54  
55 24 previous births, as well as on each child's sex, gestational age, weight, and mortality.[14]  
56  
57  
58  
59  
60

1  
2  
3  
4 1 Time of conception is based on ultrasound estimates in early pregnancy, or information on last  
5  
6 2 menstrual period.  
7

8  
9 3 Information on redeemed prescriptions was retrieved from the National Prescription Register,  
10  
11 4 which holds information on date of redemption, quantity, strength, and form.[16] Drugs are coded  
12  
13 5 in accordance with the Anatomical Therapeutic Chemical (ATC) classification.  
14

15 6 The Danish National Hospital Register contains information on diagnoses of somatic  
16  
17 7 admissions and outpatients at all Danish hospitals since 1977[15] in accordance with the Danish  
18  
19 8 revision of the 10th International Classification of Diseases (ICD)-system. We used primary  
20  
21 9 discharge diagnoses and disregarded secondary diagnoses, because secondary diagnoses in general  
22  
23 10 are not validated. We identified diagnoses of pre-eclampsia and eclampsia, migraine, essential  
24  
25 11 tremor, arrhythmias and maternal smoking. Pre-eclampsia and eclampsia were defined as women  
26  
27 12 diagnosed with O13, O14, or O15. Migraine was defined as G43 or G44, essential tremor as G250  
28  
29 13 and arrhythmias as I47, I48, and I49. Maternal smoking was defined as women diagnosed with  
30  
31 14 UT00, UT20, UT21, UT22, and UT23.  
32  
33  
34

35 15

### 36 37 16 **Identification of Exposure**

38  
39  
40 17 We defined exposure to beta-blockers as the redemption of at least two prescriptions between six  
41  
42 18 months before conception and the twentieth week of gestation. At least one of these prescriptions  
43  
44 19 had to be redeemed between conception and the twentieth week of gestation.  
45

46 20 We assessed exposure to beta-blockers by identifying redeemed prescriptions with ATC code C07.  
47  
48 21 Furthermore, we identified the most frequently redeemed beta-blockers in Denmark: labetalol  
49  
50 22 (C07AG01), metoprolol (C07AB02), atenolol (C07AB03), propranolol (C07AA05), pindolol  
51  
52 23 (C07AA03), and sotalol (C07AA07). Fewer than 50 pregnancies were exposed to any of the  
53  
54 24 remaining beta-blockers.  
55  
56  
57  
58  
59  
60

1 We divided beta-blocker exposure into exposure to labetalol and exposure to other beta-  
2 blockers. The latter group was formed because there were few redeemed prescriptions of individual  
3 beta-blockers other than labetalol. We compared risks associated with exposure to beta-blockers  
4 with exposure to methyldopa (C02AB01, C02AB02), calcium channel blockers (C08C), and ACE  
5 inhibitors (C09A) to assess possible confounding by indication.

6 Maternal diabetes mellitus was defined as redeeming a prescription for insulin or an insulin  
7 analogue (ATC code A10A). Furthermore, we assessed co-medication with statins (ATC code C10)  
8 and antiobesity drugs (ATC code A08A). We identified pregnant women redeeming prescriptions  
9 with these drugs in order to adjust for diabetes mellitus, obesity, and statin use since these women  
10 have different risk profiles for the defined outcomes.

## 11

### 12 **Definition of Outcomes**

13 Being born SGA was defined as having a birth weight below the tenth percentile for the  
14 corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup> gestational week.  
15 Perinatal mortality was defined as either death occurring within the first 28 days of life, or stillbirth.  
16 Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation,  
17 but since then stillbirth is recorded for deaths after 22 gestational weeks.[20]

### 18

### 19 **Statistical analyses**

20 Data were managed and analysed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Logistic  
21 regression models were developed for dichotomous variables adjusted for maternal age, year of  
22 conception, annual household income, parity, and educational level (model 1). Maternal age was  
23 divided into five groups: <20, 21-25, 26-30, 31-35, >35 years (no missing values). Annual  
24 household income at year of birth was divided into quartiles (1266 missing values). Subjects were

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 divided into quartiles according to the number of previous births, including stillbirths (37 missing  
2 values): 0, 1, 2,  $\geq 3$  births. Year of conception was ordered into three categories (1994-1998, 1999-  
3 2003, and 2004-2008). Educational level was divided into tertiles by highest level of education  
4 achieved at the year of birth. For missing information we used information from the following  
5 calendar year (32 745 missing values).

6 We constructed a separate logistic regression model (model 2) including the socio-economic  
7 variables in model 1 and additional confounding variables: smoking status, co-medication (yes/no)  
8 with statins, antiobesity drugs, insulin and insulin analogues, and diagnoses of pre-  
9 eclampsia/eclampsia. These confounders were included in model 2 due to the high frequency of  
10 missing data, because information on smoking and diagnoses of pre-eclampsia/eclampsia were not  
11 available for the years 1995 and 2008. Maternal smoking was divided into four categories according  
12 to the number of cigarettes smoked daily (0, 1-10, 11-20,  $>20$ ).

13 When estimating the risk of perinatal mortality, analyses were further adjusted for previous  
14 stillbirths. Odds ratios are presented with 95% confidence intervals (95% CIs). For description of  
15 basic characteristics we used frequencies with percentages. We used Chi-square tests to analyse  
16 differences in the proportions of the different classes of categorical baseline characteristics.  
17 Statistical significance was defined as  $p < 0.05$ . All tests were two-sided.

18 In addition, we carried out a propensity score-matched regression analysis to consolidate our  
19 findings. We calculated a propensity score for the likelihood of redeeming a beta-blocker during  
20 pregnancy by multivariate logistic regression conditional on baseline covariates. Using the Greedy  
21 matching macro (<http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas>), we  
22 matched each case to four controls on the basis of the propensity score (table 1). We did not match  
23 on diagnoses of pre-eclampsia/eclampsia since a large fraction of these cases redeemed beta-blocker  
24 prescriptions.

1  
2  
3  
4 1  
5  
67 **RESULTS**  
8  
9

10 Table 1 presents maternal characteristics in beta-blocker-exposed and unexposed women (number  
11 and percentage of pregnancies). We identified 2381 pregnancies exposed to only one beta-blocker,  
12 1452 exposed to labetalol only, and 929 exposed to other beta-blockers. 98 pregnancies were  
13 exposed to more than one beta-blocker. We found 515 pregnancies exposed to methyldopa, 86  
14 pregnancies to calcium channel blockers (CCBs), and 48 pregnancies exposed to ACE inhibitors.  
15 Women exposed to beta-blockers during pregnancy were older, had higher income, and higher  
16 parity than unexposed women. The proportions of women redeeming prescriptions for statins,  
17 antiobesity preparations, and insulins were higher among the beta-blocker-exposed group. The  
18 proportion of pregnancies complicated by pre-eclampsia was higher among beta-blocker-exposed  
19 pregnancies. There was no difference in smoking prevalence between beta-blocker-exposed and  
20 unexposed women (table 1).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1

2

3

4

	Beta-blocker-exposed (n=2459)	Beta-blocker-unexposed (n=909228)		Propensity matched (n=9662)	
Characteristics	n (%)	n (%)	p-value <sup>a</sup>	n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001		0.991
Low	739 (30.05)	311 600 (35.45)		2965 (30.69)	
Medium	972 (39.53)	285 450 (32.47)		3883 (40.19)	
High	707 (28.75)	279 431 (31.79)		2814 (29.12)	
<b>Annual household income (GBP)</b>			<0.001		0.989
0- 36 770	509 (23.99)	226 228 (24.84)		1924 (19.91)	
36 771 – 52 703	594 (24.16)	227 195 (24.96)		2337 (24.19)	
52 704 – 74 699	662 (26.92)	227 089 (24.94)		2631 (27.23)	
≥ 74 700	693 (28.18)	227 448 (24.98)		2770 (28.67)	
<b>Parity</b>			<0.001		0.998
1	900 (36.60)	394 661 (43.29)		3487 (28.87)	
2	918 (37.33)	338 989 (37.18)		3658 (30.28)	
3	455 (18.50)	129 482 (14.20)		1788 (14.80)	
>3	186 (7.56)	46 057 (5.05)		729 (6.04)	
<b>Age (years)</b>			<0.001		1.000
<20	18 (0.73)	26 321 (2.89)		68 (0.56)	
21-25	174 (7.07)	147 298 (16.16)		699 (5.79)	
26-30	700 (28.47)	350 105 (38.40)		2757 (22.82)	
31-35	930 (37.82)	281 154 (30.84)		3665 (30.34)	
>35	637 (24.90)	104 339 (11.44)		2473 (20.47)	
<b>Daily cigarettes<sup>b</sup></b>			0.427		0.385
0	1548 (80.29)	572 642 (81.15)		6140 (81.81)	
1-10	251 (13.02)	90 033 (12.76)		913 (12.16)	
11-20	114 (5.19)	36201 (5.13)		394 (5.25)	
>20	15 (0.78)	4849 (0.69)		59 (0.79)	
<b>Statins</b>			<0.001		0.492
Used	5 (0.20)	111 (0.01)		14 (0.14)	
Not used	2454 (99.8)	909 115 (99.99)		9648 (99.86)	
<b>Antiobesity preparations (A10)</b>			0.018		0.251
Used	9 (0.40)	1539 (0.17)		23 (0.24)	
Not used	2450 (99.6)	907 687 (99.83)		9639 (99.76)	
<b>Insulins and analogues</b>			<0.001		0.782
Used	101 (4.11)	4208 (0.46)		412 (4.14)	
Not used	2358 (95.89)	905 018 (99.53)		9250 (95.74)	
<b>Pre-eclampsia diagnosis(O13-O15)</b>			<0.001		

9

Yes	99 (4.03)	7806 (0.86)	-
No	2360 (95.97)	901 420 (99.14)	-

<sup>a</sup>Chi-square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

Women redeeming labetalol prescriptions were older, had a higher education level, and a higher prevalence of preeclampsia and smoking than women exposed to other beta-blockers (table 2). The proportion of women redeeming prescriptions for insulin was larger among the labetalol-exposed group. There was no difference in income or co-medication with statins and antiobesity preparations between the two groups. Diagnoses of migraine and arrhythmias were more common among women exposed to any other beta-blocker. Women exposed to other beta-blockers had higher parity than those exposed to labetalol.

**Table 2.** Basic characteristics for pregnancies exposed to labetalol, compared with pregnancies exposed to other beta-blockers.

Characteristics	Labetalol (n=1452) n (%)	Other beta-blockers (n=929) n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001
Low	391 (26.93)	321 (34.55)	
Medium	571 (39.33)	369 (39.72)	
High	462 (31.82)	226 (24.33)	
<b>Annual household income (GBP)</b>			0.138
0 – 36 770	202 (13.91)	289 (31.11)	
36 771 – 52 703	223 (15.36)	357 (38.43)	
52 704 – 74 699	228 (15.70)	413 (44.46)	
≥74 700	275 (19.94)	393 (42.30)	
<b>Parity</b>			0.004
0	512 (35.26)	363 (39.07)	
1	586 (40.36)	308 (33.15)	
2	256 (17.63)	179 (19.27)	
≥3	98 (6.75)	79 (8.50)	
<b>Age (years)</b>			<0.001
<20	7 (0.58)	10 (1.08)	

1				
2				
3				
4	21-25	69 (4.75)	97 (10.44)	
5	26-30	406 (27.96)	275 (29.60)	
6	31-35	586 (40.36)	314 (33.79)	
7	>35	384 (26.45)	233 (25.08)	
8				
9	<b>Daily cigarettes<sup>b</sup></b>			<0.001
10	0	933 (64.26)	565 (60.82)	
11	1-10	130 (8.95)	112 (12.06)	
12	11-20	44 (3.03)	62 (6.67)	
13	>20	9 (6.19)	6 (0.65)	
14				
15	<b>Antiobesity drugs</b>			0.052
16	Yes	5 (0.34)	9 (0.97)	
17	No	1447 (99.66)	920 (99.03)	
18				
19	<b>Statins</b>			0.261
20	Yes	5 (0.34)	1 (0.10)	
21	No	1447 (99.66)	928 (99.90)	
22				
23	<b>Insulins and analogues</b>			<0.001
24	Yes	83 (5.72)	16 (1.72)	
25	No	1369 (94.28)	913 (92.28)	
26				
27	<b>Migraine</b>			<0.001
28	Yes	26 (1.79)	46 (4.95)	
29	No	1426 (98.21)	883 (95.05)	
30				
31	<b>Pre-eclampsia diagnosis</b>			0.001
32	Yes	74 (5.10)	21 (2.26)	
33	No	1378 (94.90)	908 (97.84)	
34				
35	<b>Arrhythmia</b>			<0.001
36	Yes	23 (1.58)	82 (8.83)	
37	No	1429 (98.42)	847 (91.17)	
38				
39	<b>Essential tremor</b>			0.030
40	Yes	-	3 (0.33)	
41	No	1452 (100)	926 (99.67)	

<sup>a</sup>Chi square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

Table 3 presents ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure to beta-blockers during pregnancy.

## 1 SGA

2 We found 93 662 children born SGA in the unexposed population (table 3). There were 446  
3 children born SGA among pregnancies exposed to some kind of beta-blocker. We found a higher  
4 proportion of SGA among women exposed to beta-blockers compared with unexposed women.  
5 Women exposed to labetalol or to other beta-blockers had similarly higher odds ratios than  
6 unexposed women (table 3).

## 8 Preterm birth

9 We identified 109 163 preterm births in the unexposed population (table 3). There were 697 preterm  
10 births among pregnancies exposed to beta-blockers. We found an association between preterm birth  
11 and beta-blocker exposure compared with unexposed women. Those exposed to labetalol or to other  
12 beta-blockers had similarly higher odds ratios than unexposed women (table 3).

## 14 Perinatal mortality

15 We identified 6048 perinatal deaths in the unexposed population (table 3). There were 44 perinatal  
16 deaths among infants exposed to beta-blockers. We found a higher rate of perinatal mortality  
17 amongst women exposed to beta-blockers (table 3).

18 When stratifying for different beta-blockers we found 30 perinatal deaths among labetalol-  
19 exposed pregnancies. Labetalol exposure was associated with increased risk of perinatal mortality  
20 (table 3).

21 We identified 13 perinatal deaths among pregnancies exposed to other beta-blockers.  
22 Exposure to other beta-blockers was found to be significantly associated with perinatal mortality in  
23 the unadjusted model and model 1. However, adjusting our analysis for additional confounding  
24 variables (Model 2) rendered the association statistically insignificant (table 3).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

## 2 **Other analyses**

3 We identified 515 pregnancies exposed to methyldopa (table 3). We found 61 children born SGA,  
4 216 preterm births and 4 perinatal deaths among these pregnancies. We found a positive association  
5 between children born SGA and exposure to methyldopa, and between methyldopa exposure and  
6 increased risk of preterm birth. Exposure to methyldopa during pregnancy was not significantly  
7 associated with perinatal mortality (table 3).

8

9 **Table 3.** ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure to beta-  
10 blockers during pregnancy.

11

**Table 3 Odds Ratios (ORs) with 95% CI for SGA, preterm birth and perinatal death for exposure to beta-blockers during pregnancy.**

Analyses are adjusted for maternal age, household income, educational level, parity, birth year and prior stillbirths.  
\*Model 2 is furthermore adjusted for smoking and comedication with statins, antiobesity preparations, insulins and diagnoses of pre-eclampsia/eclampsia. The cohort in model 2 comprises all births between 1996 and 2007 (n=778 204).

Exposure	N (%)	Crude OR (95% CI)	Adjusted (model 1) OR (95% CI)	Adjusted (model 2) OR (95% CI)
SGA				
Unexposed (n=909 226)	93 662 (10.30)	Reference	Reference	Reference
All beta-blockers (n=2459)	446 (18.14)	1.93 (1.74-2.14)	1.99 (1.79-2.21)	1.97 (1.75-2.23)
Labetalol only (n=1452)	258 (17.77)	1.88 (1.64-2.15)	1.95 (1.70-2.24)	2.02 (1.72-2.37)
Other beta-blockers (n=929)	179 (19.27)	2.08 (1.76-2.44)	2.11 (1.79-2.49)	2.01 (1.66-2.43)
Methyldopa (n= 515)	61 (11.84)	1.17 (0.89-1.53)	1.32 (1.01-1.73)	1.43 (1.04-1.96)
CCBs (n=86)	21 (24.42)	2.30 (1.42-3.73)	2.24 (1.36-3.67)	1.88 (1.02-3.49)
Preterm birth				
Unexposed (n=909 226)	109 163 (12.01)	Reference	Reference	Reference
All beta-blockers (n=2459)	697 (28.34)	2.9 (2.66-3.14)	2.71 (2.48-2.97)	2.26 (2.03-2.52)
Labetalol only (n=1452)	473 (32.58)	3.54 (3.17-3.95)	3.33 (2.98-3.72)	2.74 (2.39-3.13)
Other beta-blockers (n=929)	206 (22.17)	2.08 (1.78-2.43)	1.93 (1.65-2.26)	1.69 (1.41-2.03)
Methyldopa (n= 515)	216 (41.94)	5.29 (4.44-6.31)	5.03 (4.21-6.01)	4.21 (3.38-5.23)
CCBs (n=86)	26 (30.23)	2.55 (1.63-3.99)	2.50 (1.60-3.89)	2.15 (1.26-3.67)
Perinatal mortality				
Unexposed (n=909 226)	6048 (0.67)	Reference	Reference	Reference
All beta-blockers (n=2459)	44 (1.79)	2.72 (2.02-3.67)	2.69 (1.98-3.65)	1.89 (1.25-2.84)
Labetalol only (n=1452)	30 (2.07)	3.15 (2.19-4.52)	3.24 (2.25-4.67)	2.08 (1.26-3.44)
Other beta-blockers (n=929)	13 (1.39)	2.12 (1.22-3.66)	1.92 (1.08-3.40)	1.72 (0.85-3.48)
Methyldopa (n= 515)	4 (0.78)	1.15 (0.43-3.07)	1.16 (0.43-3.12)	0.35 (0.05-2.50)
CCBs (n=86)	1 (1.16)	1.78 (0.25-12.57)	2.00 (0.28-14.83)	3.26 (0.45-23.77)

1

2

3

4 We found 86 pregnancies exposed to calcium channel blockers (table 3). These included 17

5 children born SGA, 18 preterm births and 1 perinatal death. We found an association between

6 exposure to calcium channel blockers and children born SGA in all models.

7 Additionally, we found an association between exposure to calcium channel blockers and

8 increased risk of preterm birth in all models. As with methyldopa, exposure to calcium channel

9 blockers during pregnancy was not found to be associated with perinatal mortality (table 3).

10 Analyses for exposure to ACE inhibitors were not performed since we identified only 48

11 pregnancies exposed to them.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Post hoc we analysed the effect of exposure to all beta-blockers using a propensity score-matched control group (Table 1) and found similar results to those of the primary analyses: SGA, OR=1.93 (95% CI, 1.71–2.19); preterm birth, OR=2.40 (95% CI, 2.16–2.67); perinatal mortality, OR=3.22 (95% CI, 2.15–4.82).

## DISCUSSION

In the present study, which we believe to be the largest of its kind to date, we found an association between redeeming prescriptions of beta-blockers during pregnancy and being born SGA, preterm birth, and perinatal mortality. In addition, we found an association between redeeming prescriptions of methyldopa and calcium channel blockers, being born SGA, and preterm birth. Methyldopa and calcium channel blockers were not found to be associated with perinatal mortality.

We found exposure to any beta-blocker to be associated with being born SGA. Our results are in accordance with a recent study reporting increased risk of being born SGA among pregnancies exposed to selective beta-blockers (OR=6.00; 95% CI, 1.06–33.87) and labetalol (OR=2.26; 95% CI, 1.04–4.88).[9] Labetalol is generally considered safe for use during pregnancy.[1,8,21]

Exposure to beta-blockers was found to be associated with preterm birth. When stratifying for different beta-blockers we found an increased risk of preterm birth after exposure to labetalol, and all other beta-blockers, respectively.

We found an association between exposure to beta-blockers and perinatal mortality. When stratifying for different beta-blockers we found this association to be statistically significant for exposure to labetalol and other beta-blockers. When adjusting our analysis for maternal co-morbidity, co-medication, and smoking, only labetalol was found to be associated with perinatal mortality.

1  
2  
3  
4 1 Methyldopa is mainly used to treat chronic hypertension during pregnancy as first-line  
5  
6 2 therapy.[1] Previous studies did not find any associations between methyldopa exposure and being  
7  
8 3 born SGA or preterm birth.[1,3] Methyldopa has not been found to have effects on placental  
9  
10 4 haemodynamics.[1] However, a recent case-control study reported an increased risk of being born  
11  
12 5 SGA among pregnancies exposed to centrally acting adrenergic agents during the second and third  
13  
14 6 trimesters[9]: OR=1.70 (95% CI, 1.00–2.89). We found that methyldopa exposure was associated  
15  
16 7 with being born SGA and preterm birth. This could be due to indicative antihypertensive treatment  
17  
18 8 with methyldopa in pregnant women with diabetes or pregnancy related diabetes. The prevalence of  
19  
20 9 diabetes among methyldopa-exposed pregnancies was found to be higher: 11.1% compared with  
21  
22 10 3.9% among beta-blocker-exposed pregnancies. Increased risk of preterm birth was still seen after  
23  
24 11 adjusting our analyses for additional confounding variables in model 2. We found no association  
25  
26 12 between exposure to methyldopa and perinatal mortality. These findings are consistent with those of  
27  
28 13 a previous study.[3]

29  
30  
31  
32  
33 14 Calcium channel blockers are considered to be safe during pregnancy.[3,22] We found that  
34  
35 15 exposure to calcium channel blockers was associated with being born SGA and with preterm birth.  
36  
37 16 The risk of being born SGA and preterm of birth remained after adjusting our analyses for  
38  
39 17 additional confounding variables in model 2. We found no statistically significant association  
40  
41 18 between calcium channel blocker exposure during pregnancy and perinatal mortality.

42  
43  
44 19 We chose to analyse two outcomes previously reported to be associated with beta-blocker  
45  
46 20 exposure during pregnancy —SGA and preterm birth[1,10,23] — that have been associated with  
47  
48 21 increased perinatal mortality in previous studies.[12,13] Therefore we investigated the risk of  
49  
50 22 perinatal mortality among beta-blocker-exposed pregnancies. We compared risks associated with  
51  
52 23 exposure to beta-blockers with exposure to methyldopa and calcium channel blockers to assess  
53  
54 24 possible confounding by indication. Our analyses show a similar risk of being born SGA and an  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 1 increased risk of preterm birth for all recommended agents during pregnancy. There are various  
5  
6 2 possible explanations for this finding. It is possible that the underlying indication for treatment,  
7  
8 3 maternal disease, is the true risk factor. Possible maternal diseases include hypertension, either  
9  
10 4 predated or complicating pregnancy. Accordingly, we were not able to rule out a potential effect of  
11  
12 5 maternal disease on perinatal outcomes.

13  
14  
15 6 We found an association between exposure to beta-blockers during pregnancy and perinatal  
16  
17 7 mortality. This association was not found for exposure to methyldopa and calcium channel  
18  
19 8 blockers, which might be due to the small number of cases.

20  
21  
22 9 We believe that the similar risks found for exposure to the various beta-blockers and SGA,  
23  
24 10 preterm birth, and perinatal mortality are a class effect. This seems to be true in spite of statistically  
25  
26 11 significant differences in the basic characteristics of women exposed to labetalol and those exposed  
27  
28 12 to other beta-blockers (table 2). After adjustments were made for these variables, we found  
29  
30 13 comparable risk profiles for labetalol-exposed pregnancies and pregnancies exposed to other beta-  
31  
32 14 blockers. Most beta-blockers are known to cross the placenta,[21,24] and effects on placental  
33  
34 15 haemodynamics have been observed in both human and animal studies. A mechanism has been  
35  
36 16 proposed of diminished placental blood flow due to the selective vasoconstriction of placental  
37  
38 17 vessels by beta-blockers without intrinsic sympathomimetic activity.[24] This effect on placental  
39  
40 18 haemodynamics could explain growth retardation of foetuses exposed to beta-blockers during  
41  
42 19 pregnancy and might result in children being born SGA and preterm.

43  
44  
45  
46 20 We defined exposure as redemption of at least two prescriptions between six months before  
47  
48 21 conception and the twentieth week of gestation. At least one of these prescriptions had to be  
49  
50 22 redeemed between conception and twentieth week of gestation. We believe that this model  
51  
52 23 increases the probability of identifying continuous use that extends into pregnancy.

1  
2  
3  
4 1 The rate of perinatal mortality in Denmark is low (table 3).[25] A large number of women  
5  
6 2 exposed to beta-blockers, methyldopa, and calcium channel blockers are therefore needed to  
7  
8 3 identify a possible risk increase associated with these outcomes. Our cohort comprises all births in  
9  
10 4 Denmark between 1995 and 2008. This minimises confounding due to race, educational level, and  
11  
12 5 other socio-economic factors. The national Danish registers cover the entire nation and are  
13  
14 6 considered valid. As part of the national health care reimbursement scheme, Danish pharmacies are  
15  
16 7 required by law to register all redeemed prescriptions. Approximately 97.5% of all redeemed  
17  
18 8 prescriptions are registered in the Danish Prescription register.[16] Our study includes data on  
19  
20 9 exposure to beta-blockers based on information on prescriptions paid for at the pharmacy, and not  
21  
22 10 only prescribed by the physician, thereby increasing the probability of exposure. Furthermore, our  
23  
24 11 study was not confounded by recall bias since information was recorded prospectively. The Danish  
25  
26 12 Fertility Database contains more than 99% of all births during the study period.[14]

27  
28  
29  
30  
31 13 Limitations of our study include missing information on maternal weight and alcohol  
32  
33 14 consumption. We were unable to adjust for treatment indication and severity of maternal disease.  
34  
35 15 Given the study design, we were not able to address this issue further, nor were we able to rule out  
36  
37 16 confounding by indication, the underlying maternal disease, as a possible explanation for our  
38  
39 17 findings. Consequently we were unable to differentiate between a possible class effect of beta-  
40  
41 18 blockers and the effect of the underlying maternal disease.

42  
43  
44 19 Unfortunately information on diagnoses of essential hypertension was not available, since  
45  
46 20 these are known risk factors for our primary outcomes.

47  
48 21 The prevalence of pre-eclampsia and eclampsia in the cohort is based on primary discharge  
49  
50 22 diagnoses from hospital admissions. We did not use secondary diagnoses, since these in general are  
51  
52 23 not validated. We estimated exposure from National Prescription Registry data, which contains  
53  
54 24 information on all redeemed prescriptions.[16] Overestimation of exposure is therefore a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

possibility, since we cannot adjust for a potential lack of compliance. However, in a study by Olesen et al. conducted in a cohort of pregnant Danish women in the county of North Jutland,[26] compliance with prescribed beta-blockers was estimated to be complete, strengthening the validity of our analyses. Furthermore, overestimation of exposure would bias the estimates towards unity.

There is a general consensus that labetalol is safer than other beta-blockers during pregnancy and this drug is rapidly becoming the first-line choice in conditions such as chronic hypertension during pregnancy.[21,23] We found an association between redeeming prescriptions for beta-blockers and being born SGA, preterm birth, and perinatal mortality. Risk profiles for pregnancies exposed to labetalol and to other beta-blockers were similar. The increasing use and uncertainty of effects and possible side effects of treatment with beta-blockers during pregnancy call for further studies to validate our findings.

### Conflicts of interests

The authors have no relevant conflict of interests.

### Funding

The project was sponsored by the Capital Region of Copenhagen.

### Contributorship Statement

KMP, EJS, JTA, MP, KB, LK, CTP, HEP

KMP, EJS, JTA and HEP conceptualized the study. MP, KB, LK and CTP assisted with the study design. KMP performed the analyses assisted by EJS and JTA, MP, KB, LK, CTP and HEP assisted in the interpretation. KMP, EJS, JTA, MP, KB, LK, CTP and HEP wrote and revised the final manuscript. Figure design was done by KMP, EJS, JTA, MP, KB, LK, CTP and HEP. All authors approved the final version to be published.

1  
2  
3  
4 **1 REFERENCES**  
5  
6

- 7 1 Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 1996 Jul  
8  
9 25;335(4):257-65.  
10  
11  
12 2 Magee LA, Ornstein MP, von DP. Fortnightly review: management of hypertension in  
13  
14 pregnancy. *BMJ* 1999 May 15;318(7194):1332-6.  
15  
16  
17  
18 3 Afifi Y, Churchill D. Pharmacological treatment of hypertension in pregnancy. *Curr Pharm*  
19  
20 *Des* 2003;9(21):1745-53.  
21  
22  
23 4 Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during  
24  
25 pregnancy. *Cochrane Database Syst Rev* 2003;(3):CD002863.  
26  
27  
28  
29 5 Modi S FAU - Lowder D, Lowder DM. Medications for migraine prophylaxis.(0002-838X  
30  
31 (Print)).  
32  
33  
34 6 Lyons KE FAU - Pahwa R, Pahwa R. Pharmacotherapy of essential tremor : an overview of  
35  
36 existing and upcoming agents.(1172-7047 (Print)).  
37  
38  
39  
40 7 Sibai BM, Gonzalez AR, Mabie WC et al. comparison of labetalol plus hospitalization  
41  
42 versus hospitalization alone in the management of preeclampsia remote from term. *Obstet*  
43  
44 *Gynecol* 1987 Sep;70(3 Pt 1):323-7.  
45  
46  
47 8 Magee LA, Elran E, Bull SB et al. Risks and benefits of beta-receptor blockers for  
48  
49 pregnancy hypertension: overview of the randomized trials. *Eur J Obstet Gynecol Reprod*  
50  
51 *Biol* 2000 Jan;88(1):15-26.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 9 Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and  
2 the risk of major congenital malformations or small-for-gestational-age newborns. Birth  
3 Defects Res B Dev Reprod Toxicol 2010 Apr;89(2):147-54.
- 4 10 Lydakos C, Lip GY, Beevers M et al. Atenolol and foetal growth in pregnancies complicated  
5 by hypertension. Am J Hypertens 1999 Jun;12(6):541-7.
- 6 11 Abalos E, Duley L, Steyn DW et al. Antihypertensive drug therapy for mild to moderate  
7 hypertension during pregnancy. Cochrane Database Syst Rev 2007;(1):CD002252.
- 8 12 Zeitlin J, El AM, Jarreau PH et al. Impact of foetal growth restriction on mortality and  
9 morbidity in a very preterm birth cohort. J Pediatr 2010 Nov;157(5):733-9.
- 10 13 Challis JR, Lye SJ, Gibb W et al. Understanding preterm labor. Ann N Y Acad Sci 2001  
11 Sep;943:225-34.
- 12 14 Knudsen LB. The Danish Fertility Database. Dan Med Bull 1998 Apr;45(2):221-5.
- 13 15 Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A  
14 valuable source of data for modern health sciences. Dan Med Bull 1999 Jun;46(3):263-8.
- 15 16 Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997  
16 Sep;44(4):445-8.
- 17 17 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments.  
18 Scand J Public Health 2011 Jul;39(7 Suppl):103-5.
- 19 18 Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health 2011  
20 Jul;39(7 Suppl):91-4.

- 1  
2  
3  
4 1 19 Pedersen CB, Gotzsche H, Moller JO et al. The Danish Civil Registration System. A cohort  
5  
6 2 of eight million persons. *Dan Med Bull* 2006 Nov;53(4):441-9.  
7  
8  
9  
10 3 20 Knudsen LB, Borlum KF. Monitoring perinatal mortality and perinatal care with a national  
11  
12 4 register: content and usage of the Danish Medical Birth Register. *Community Med* 1986  
13  
14 5 Feb;8(1):29-36.  
15  
16  
17 6 21 Karthikeyan VJ, Lip GY. Hypertension in pregnancy: pathophysiology and management  
18  
19 7 strategies. *Curr Pharm Des* 2007;13(25):2567-79.  
20  
21  
22 8 22 Magee LA, Schick B, Donnenfeld AE et al. The safety of calcium channel blockers in  
23  
24 9 human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol* 1996  
25  
26 10 Mar;174(3):823-8.  
27  
28  
29  
30 11 23 Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy.  
31  
32 12 *Hypertension* 2008 Apr;51(4):960-9.  
33  
34  
35  
36 13 24 Lennestall R, Otterblad OP, Kallen B. Maternal use of antihypertensive drugs in early  
37  
38 14 pregnancy and delivery outcome, notably the presence of congenital heart defects in the  
39  
40 15 infants. *Eur J Clin Pharmacol* 2009 Jun;65(6):615-25.  
41  
42  
43 16 25 World Health Organization. Levels & Trends in Child Mortality. Report 2011. Estimates  
44  
45 17 Developed by the UN Inter-agency for Child Mortality Estimation. 2011.  
46  
47 18 [http://www.who.int/child\\_adolescent\\_health/documents/child/childmortality\\_booklet\\_2011.](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf)  
48  
49 19 [pdf](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf), World Health Organization.  
50  
51 20 Ref Type: Online Source  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 26 Olesen C, Sondergaard C, Thrane N et al. Do pregnant women report use of dispensed  
2 medications? Epidemiology 2001 Sep;12(5):497-501.  
3  
4

For peer review only

1 Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide  
2 population-based cohort study  
3

4 **Kasper Meidahl Petersen MB<sup>1</sup>; Espen Jimenez-Solem MD<sup>1</sup>; Jon Trærup Andersen MD<sup>1</sup>;**  
5 **Morten Petersen MD<sup>1</sup>, PhD; Kasper Brødbæk MD<sup>1</sup>; ~~Henrik Enghusen Poulsen MD, DMSc<sup>†</sup>;~~**  
6 **Lars Køber MD, DMSc<sup>2</sup>; Christian Torp-Petersen MD, DMSc<sup>3</sup>; Henrik Enghusen Poulsen**  
7 **MD, DMSc<sup>1</sup>**  
8

#### 9 **Author affiliations**

10 1: Department of Clinical Pharmacology, Q, Rigshospitalet, University Hospital Copenhagen,  
11 Denmark

12 2: Department of Cardiology, Rigshospitalet, University Hospital Copenhagen, Denmark

13 3: Department of Cardiology, Gentofte Hospital, Gentofte, Denmark  
14

15 **Keywords (MeSH):** Adrenergic beta-antagonists, pregnancy, small for gestational age infant,  
16 premature birth, perinatal mortality.

17 **Words:** [2995](#) [3054](#)  
18

#### 19 **Correspondence to:**

20 Kasper Meidahl Petersen  
21 Department of Clinical Pharmacology, Q  
22 Rigshospitalet, University Hospital Copenhagen  
23 Tagensvej 20  
24 DK-2200 Copenhagen N  
25 Denmark  
26 Tel +45 5123 7716  
27 Fax +45 3545 2745  
28 E-mail: [kaspermeidahl@gmail.com](mailto:kaspermeidahl@gmail.com)  
29  
30  
31



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### ABSTRACT

**Objective:** To investigate the association between exposure to beta-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth, and perinatal mortality in a nationwide cohort.

**Design:** A population-based retrospective cohort study, using the Danish Fertility Database. We identified all pregnant women redeeming a prescription for beta-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes.

**Setting:** Register based survey.

**Participants:** 911685 births between 1995 and 2008 obtained from the Danish Fertility Database.

**Outcome measures:** Being born SGA was defined as having a birth weight below the tenth percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup> gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life, or stillbirth. Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks.

**Results:** We identified 2459 pregnancies exposed to beta-blockers. Beta-blocker exposure during pregnancy was found to be associated with increased risk of SGA; adjusted OR=1.97 (95% CI, 1.75–2.23), preterm birth; adjusted OR=2.26 (95% CI, 2.03–2.52) and perinatal mortality; adjusted OR=1.89 (95 % CI, 1.25–2.84). Analyses were adjusted for socio-economic and maternal variables. We found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other beta-blockers.

1 **Conclusion:** We found that exposure to beta-blockers during pregnancy was associated with being  
2 born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than  
3 other beta-blockers during pregnancy. ~~and future treatment of pregnant women with beta-blockers  
4 should therefore be based primarily on the individual needs of the mother and not the unborn child.~~

## 5 **ARTICLE SUMMARY**

### 6 **Article focus**

- 7 • There is contradictory evidence concerning the consequences of beta-blocker treatment  
8 during pregnancy.
- 9 • This survey explores the effects of beta-blocker exposure during pregnancy in a Danish birth  
10 cohort comprising all births in Denmark between 1995 and 2008. In addition we compared  
11 risks associated with exposure to labetalol with exposure to other beta-blockers.

### 12 **Key messages**

- 13 • Redeeming prescriptions of beta-blockers was found to be significantly associated with  
14 increased risk of being born SGA, preterm birth, and perinatal mortality.
- 15 • We found comparable risk profiles in labetalol-exposed pregnancies and in pregnancies  
16 exposed to any other beta-blocker.

### 17 **Strengths and limitations of this study**

- 18 • This study is the largest of its kind to date, and covers an entire nation which minimises risk  
19 of selection bias.
- 20 • Given the study design, we were not able to adjust for treatment indication and severity of  
21 maternal disease, nor were we able to rule out confounding by indication, the underlying  
22 maternal disease, as a possible explanation for our findings.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 INTRODUCTION

2 Beta-blockers are widely used in the treatment of chronic hypertension,[1-4] migraine,[5] essential  
3 tremor[6], and various other conditions. There is contradictory evidence concerning the  
4 consequences of beta-blocker treatment during pregnancy. Some studies report an association  
5 between beta-blocker treatment and small for gestational age (SGA) newborns, and preterm  
6 birth,[4,7-10] while others do not.[2,11] Preterm birth and being born SGA are both associated with  
7 increased risk of perinatal mortality.[12,13] We set out to investigate whether the use of beta-  
8 blockers during pregnancy was associated with being born SGA, preterm birth and perinatal  
9 mortality in a nationwide survey between 1995 and 2008.

10

## 11 METHOD

### 12 Study population

13 We used data obtained from three nationwide registries: the Danish Fertility Database,[14] the  
14 Danish National Hospital Register[15], and the National Prescription Register.[16] Data concerning  
15 income and educational level were obtained respectively from the Income Statistics Register[17]  
16 and the Danish Education register,[18] both of which are provided by Statistics Denmark. In  
17 Denmark all citizens are given a unique ten-digit identification number at birth.[19] This number  
18 can be used to link information between nationwide registers.

19 Using the Danish Fertility Database we identified 974 805 births between 1995 and 2008. We  
20 removed 52 603 records lacking information on pregnancy duration and 7681 records with coding  
21 errors. In addition, we excluded 2836 records with pregnancy-induced hypertension, defined as  
22 having redeemed an antihypertensive drug prescription after the twentieth week of gestation, but  
23 never before. The final study population thus comprised 911 685 births.

1 The Danish Fertility Database contains information on maternal age, date of birth, and  
2 previous births, as well as on each child's sex, gestational age, weight, and mortality.[14]  
3 Time of conception is based on ultrasound estimates in early pregnancy, or information on last  
4 menstrual period.

5 Information on redeemed prescriptions was retrieved from the National Prescription Register,  
6 which holds information on date of redemption, quantity, strength, and form.[16] Drugs are coded  
7 in accordance with the Anatomical Therapeutic Chemical (ATC) classification.

8 The Danish National Hospital Register contains information on diagnoses of somatic  
9 admissions and outpatients at all Danish hospitals since 1977[15] in accordance with the Danish  
10 revision of the 10th International Classification of Diseases (ICD)-system. [We used primary](#)  
11 [discharge diagnoses and disregarded secondary diagnoses, because secondary diagnoses in general](#)  
12 [are not validated. We identified diagnoses of pre-eclampsia and eclampsia, migraine, essential](#)  
13 [tremor, arrhythmias and maternal smoking.](#) Pre-eclampsia and eclampsia were defined as women  
14 diagnosed with O13, O14, or O15. Migraine was defined as G43 or G44, essential tremor as G250  
15 and arrhythmias as I47, I48, and I49. Maternal smoking was defined as women diagnosed with  
16 UT00, UT20, UT21, UT22, and UT23.

## 18 **Identification of Exposure**

19 We defined exposure to beta-blockers as the redemption of at least two prescriptions between six  
20 months before conception and the twentieth week of gestation. At least one of these prescriptions  
21 had to be redeemed between conception and the twentieth week of gestation.

22 We assessed exposure to beta-blockers by identifying redeemed prescriptions with ATC code C07.  
23 Furthermore, we identified the most frequently redeemed beta-blockers in Denmark: labetalol  
24 (C07AG01), metoprolol (C07AB02), atenolol (C07AB03), propranolol (C07AA05), pindolol

1 (C07AA03), and sotalol (C07AA07). Fewer than 50 pregnancies were exposed to any of the  
2 remaining beta-blockers.

3 We divided beta-blocker exposure into exposure to labetalol and exposure to other beta-  
4 blockers. The latter group was formed because there were few redeemed prescriptions of individual  
5 beta-blockers other than labetalol. We compared risks associated with exposure to beta-blockers  
6 with exposure to methyldopa (C02AB01, C02AB02), calcium channel blockers (C08C), and ACE  
7 inhibitors (C09A) to assess possible confounding by indication.

8 Maternal diabetes mellitus was defined as redeeming a prescription for insulin or an insulin  
9 analogue (ATC code A10A). Furthermore, we assessed co-medication with statins (ATC code C10)  
10 and antiobesity drugs (ATC code A08A). We identified pregnant women redeeming prescriptions  
11 with these drugs in order to adjust for diabetes mellitus, obesity, and statin use since these women  
12 have different risk profiles for the defined outcomes.

### 14 **Definition of Outcomes**

15 Being born SGA was defined as having a birth weight below the tenth percentile for the  
16 corresponding gestational week. Preterm birth was defined as birth before the 37<sup>th</sup> gestational week.  
17 Perinatal mortality was defined as either death occurring within the first 28 days of life, or stillbirth.  
18 Before 2004, foetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation,  
19 but since then stillbirth is recorded for deaths after 22 gestational weeks.[20]

### 21 **Statistical analyses**

22 Data were managed and analysed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Logistic  
23 regression models were developed for dichotomous variables adjusted for maternal age, year of  
24 conception, annual household income, parity, and educational level (model 1). Maternal age was

1 divided into five groups: <20, 21-25, 26-30, 31-35, >35 years (no missing values). Annual  
2 household income at year of birth was divided into quartiles (1266 missing values). Subjects were  
3 divided into quartiles according to the number of previous births, including stillbirths (37 missing  
4 values): 0, 1, 2,  $\geq 3$  births. Year of conception was ordered into three categories (1994-1998, 1999-  
5 2003, and 2004-2008). Educational level was divided into tertiles by highest level of education  
6 achieved at the year of birth. For missing information we used information from the following  
7 calendar year (32 745 missing values).

8 We constructed a separate logistic regression model (model 2) including the socio-economic  
9 variables in model 1 and additional confounding variables: smoking status, co-medication (yes/no)  
10 with statins, antiobesity drugs, insulin and insulin analogues, and diagnoses of pre-  
11 eclampsia/eclampsia. These confounders were included in model 2 due to the high frequency of  
12 missing data, because information on smoking and diagnoses of pre-eclampsia/eclampsia were not  
13 available for the years 1995 and 2008. Maternal smoking was divided into four categories according  
14 to the number of cigarettes smoked daily (0, 1-10, 11-20, >20).

15 When estimating the risk of perinatal mortality, analyses were further adjusted for previous  
16 stillbirths. Odds ratios are presented with 95% confidence intervals (95% CIs). For description of  
17 basic characteristics we used frequencies with percentages. We used Chi-square tests to analyse  
18 differences in the proportions of the different classes of categorical baseline characteristics.  
19 Statistical significance was defined as  $p < 0.05$ . All tests were two-sided.

20 In addition, we carried out a propensity score-matched regression analysis to consolidate our  
21 findings. We calculated a propensity score for the likelihood of redeeming a beta-blocker during  
22 pregnancy by multivariate logistic regression conditional on baseline covariates. Using the Greedy  
23 matching macro (<http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas>), we  
24 matched each case to four controls on the basis of the propensity score (table 1). We did not match

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 on diagnoses of pre-eclampsia/eclampsia since a large fraction of these cases redeemed beta-blocker  
2 prescriptions.

3

## 4 **RESULTS**

5 Table 1 presents maternal characteristics in beta-blocker-exposed and unexposed women (number  
6 and percentage of pregnancies). We identified 2381 pregnancies exposed to only one beta-blocker,  
7 1452 exposed to labetalol only, and 929 exposed to other beta-blockers. 98 pregnancies were  
8 exposed to more than one beta-blocker. We found 515 pregnancies exposed to methyldopa, 86  
9 pregnancies to calcium channel blockers (CCBs), and 48 pregnancies exposed to ACE inhibitors.  
10 Women exposed to beta-blockers during pregnancy were older, had higher income, and higher  
11 parity than unexposed women. The proportions of women redeeming prescriptions for statins,  
12 antiobesity preparations, and insulins were higher among the beta-blocker-exposed group. The  
13 proportion of pregnancies complicated by pre-eclampsia was higher among beta-blocker-exposed  
14 pregnancies. There was no difference in smoking prevalence between beta-blocker-exposed and  
15 unexposed women (table 1).

16

17

18

19

20

21

22

23

24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Beta-blocker-exposed (n=2459)	Beta-blocker-unexposed (n=909228)		Propensity matched (n=9662)	
Characteristics	n (%)	n (%)	p-value <sup>a</sup>	n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001		0.991
Low	739 (30.05)	311 600 (35.45)		2965 (30.69)	
Medium	972 (39.53)	285 450 (32.47)		3883 (40.19)	
High	707 (28.75)	279 431 (31.79)		2814 (29.12)	
<b>Annual household income (GBP)</b>			<0.001		0.989
0- 36 770	509 (23.99)	226 228 (24.84)		1924 (19.91)	
36 771 – 52 703	594 (24.16)	227 195 (24.96)		2337 (24.19)	
52 704 – 74 699	662 (26.92)	227 089 (24.94)		2631 (27.23)	
≥ 74 700	693 (28.18)	227 448 (24.98)		2770 (28.67)	
<b>Parity</b>			<0.001		0.998
1	900 (36.60)	394 661 (43.29)		3487 (28.87)	
2	918 (37.33)	338 989 (37.18)		3658 (30.28)	
3	455 (18.50)	129 482 (14.20)		1788 (14.80)	
>3	186 (7.56)	46 057 (5.05)		729 (6.04)	
<b>Age (years)</b>			<0.001		1.000
<20	18 (0.73)	26 321 (2.89)		68 (0.56)	
21-25	174 (7.07)	147 298 (16.16)		699 (5.79)	
26-30	700 (28.47)	350 105 (38.40)		2757 (22.82)	
31-35	930 (37.82)	281 154 (30.84)		3665 (30.34)	
>35	637 (24.90)	104 339 (11.44)		2473 (20.47)	
<b>Daily cigarettes<sup>b</sup></b>			0.427		0.385
0	1548 (80.29)	572 642 (81.15)		6140 (81.81)	
1-10	251 (13.02)	90 033 (12.76)		913 (12.16)	
11-20	114 (5.19)	36201 (5.13)		394 (5.25)	
>20	15 (0.78)	4849 (0.69)		59 (0.79)	
<b>Statins</b>			<0.001		0.492
Used	5 (0.20)	111 (0.01)		14 (0.14)	
Not used	2454 (99.8)	909 115 (99.99)		9648 (99.86)	
<b>Antiobesity preparations (A10)</b>			0.018		0.251
Used	9 (0.40)	1539 (0.17)		23 (0.24)	
Not used	2450 (99.6)	907 687 (99.83)		9639 (99.76)	



<b>Insulins and analogues</b>			<0.001	0.782
Used	101 (4.11)	4208 (0.46)		412 (4.14)
Not used	2358 (95.89)	905 018 (99.53)		9250 (95.74)
<b>Pre-eclampsia <a href="#">diagnosis</a>(O13-O15)</b>			<0.001	
Yes	99 (4.03)	7806 (0.86)		-
No	2360 (95.97)	901 420 (99.14)		-

<sup>a</sup>Chi-square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

Women redeeming labetalol prescriptions were older, had a higher education level, and a higher prevalence of preeclampsia and smoking than women exposed to other beta-blockers (table 2). The proportion of women redeeming prescriptions for insulin was larger among the labetalol-exposed group. There was no difference in income or co-medication with statins and antiobesity preparations between the two groups. Diagnoses of migraine and arrhythmias were more common among women exposed to any other beta-blocker. Women exposed to other beta-blockers had higher parity than those exposed to labetalol.

**Table 2.** Basic characteristics for pregnancies exposed to labetalol, compared with pregnancies exposed to other beta-blockers.

Characteristics	Labetalol (n=1452) n (%)	Other beta-blockers (n=929) n (%)	p-value <sup>a</sup>
<b>Educational level</b>			<0.001
Low	391 (26.93)	321 (34.55)	
Medium	571 (39.33)	369 (39.72)	
High	462 (31.82)	226 (24.33)	
<b>Annual household income (GBP)</b>			0.138
0 – 36 770	202 (13.91)	289 (31.11)	
36 771 – 52 703	223 (15.36)	357 (38.43)	
52 704 – 74 699	228 (15.70)	413 (44.46)	
≥74 700	275 (19.94)	393 (42.30)	
<b>Parity</b>			0.004
0	512 (35.26)	363 (39.07)	
1	586 (40.36)	308 (33.15)	

2	256 (17.63)	179 (19.27)	
≥3	98 (6.75)	79 (8.50)	
<b>Age (years)</b>			<0.001
<20	7 (0.58)	10 (1.08)	
21-25	69 (4.75)	97 (10.44)	
26-30	406 (27.96)	275 (29.60)	
31-35	586 (40.36)	314 (33.79)	
>35	384 (26.45)	233 (25.08)	
<b>Daily cigarettes<sup>b</sup></b>			<0.001
0	933 (64.26)	565 (60.82)	
1-10	130 (8.95)	112 (12.06)	
11-20	44 (3.03)	62 (6.67)	
>20	9 (6.19)	6 (0.65)	
<b>Antiobesity drugs</b>			0.052
Yes	5 (0.34)	9 (0.97)	
No	1447 (99.66)	920 (99.03)	
<b>Statins</b>			0.261
Yes	5 (0.34)	1 (0.10)	
No	1447 (99.66)	928 (99.90)	
<b>Insulins and analogues</b>			<0.001
Yes	<del>136</del> 983 (5.72)	16 (1.72)	
No	<del>83</del> 1369 (94.28)	913 (92.28)	
<b>Migraine</b>			<0.001
Yes	26 (1.79)	46 (4.95)	
No	1426 (98.21)	883 (95.05)	
<b>Pre-eclampsia diagnosis</b>			0.001
Yes	<del>1378 (94.90)</del> 74 (5.10)	<del>908 (97.84)</del> 21 (2.26)	
No	<del>74 (5.10)</del> 1378 (94.90)	<del>21 (2.26)</del> 908 (97.84)	
<b>Arrhythmia</b>			<0.001
Yes	23 (1.58)	82 (8.83)	
No	1429 (98.42)	847 (91.17)	
<b>Essential tremor</b>			0.030
Yes	-	3 (0.33)	
No	1452 (100)	926 (99.67)	

<sup>a</sup>Chi square tests were used to assess the overall p value for the group comparison.

<sup>b</sup>Information on smoking was only available for 1996-2007.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Table 3 presents ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure  
2 to beta-blockers during pregnancy.

### 3 4 **SGA**

5 We found 93 662 children born SGA in the unexposed population (table 3). There were 446  
6 children born SGA among pregnancies exposed to some kind of beta-blocker. We found a higher  
7 proportion of SGA among women exposed to beta-blockers compared with unexposed women.  
8 Women exposed to labetalol or to other beta-blockers had similarly higher odds ratios than  
9 unexposed women (table 3).

### 10 11 **Preterm birth**

12 We identified 109 163 preterm births in the unexposed population (table 3). There were 697 preterm  
13 births among pregnancies exposed to beta-blockers. We found an association between preterm birth  
14 and beta-blocker exposure compared with unexposed women. Those exposed to labetalol or to other  
15 beta-blockers had similarly higher odds ratios than unexposed women (table 3).

### 16 17 **Perinatal mortality**

18 We identified 6048 perinatal deaths in the unexposed population (table 3). There were 44 perinatal  
19 deaths among infants exposed to beta-blockers. We found a higher rate of perinatal mortality  
20 amongst women exposed to beta-blockers (table 3).

21 When stratifying for different beta-blockers we found 30 perinatal deaths among labetalol-  
22 exposed pregnancies. Labetalol exposure was associated with increased risk of perinatal mortality  
23 (table 3).

1 We identified 13 perinatal deaths among pregnancies exposed to other beta-blockers.  
2 Exposure to other beta-blockers was found to be significantly associated with perinatal mortality in  
3 the unadjusted model and model 1. However, adjusting our analysis for additional confounding  
4 variables (Model 2) rendered the association statistically insignificant (table 3).

### 6 Other analyses

7 We identified 515 pregnancies exposed to methyldopa (table 3). We found 61 children born SGA,  
8 216 preterm births and 4 perinatal deaths among these pregnancies. We found a positive association  
9 between children born SGA and exposure to methyldopa, and between methyldopa exposure and  
10 increased risk of preterm birth. Exposure to methyldopa during pregnancy was not significantly  
11 associated with perinatal mortality (table 3).

13 **Table 3.** ORs with 95% CIs for SGA, preterm birth and perinatal death for exposure to beta-  
14 blockers during pregnancy.

Exposure	N (%)	Crude OR (95% CI)	Adjusted (model 1) OR (95% CI)	Adjusted (model 2) OR (95% CI)
SGA				
Unexposed (n=909 226)	93 662 (10.30)	Reference	Reference	Reference
All beta-blockers (n=2459)	446 (18.14)	1.93 (1.74-2.14)	1.99 (1.79-2.21)	1.97 (1.75-2.23)
Labetalol only (n=1452)	258 (17.77)	1.88 (1.64-2.15)	1.95 (1.70-2.24)	2.02 (1.72-2.37)
Other beta-blockers (n=929)	179 (19.27)	2.08 (1.76-2.44)	2.11 (1.79-2.49)	2.01 (1.66-2.43)
Methyldopa (n= 515)	61 (11.84)	1.17 (0.89-1.53)	1.32 (1.01-1.73)	1.43 (1.04-1.96)
CCBs (n=86)	21 (24.42)	2.30 (1.42-3.73)	2.24 (1.36-3.67)	1.88 (1.02-3.49)
Preterm birth				
Unexposed (n=909 226)	109 163 (12.01)	Reference	Reference	Reference
All beta-blockers (n=2459)	697 (28.34)	2.9 (2.66-3.14)	2.71 (2.48-2.97)	2.26 (2.03-2.52)
Labetalol only (n=1452)	473 (32.58)	3.54 (3.17-3.95)	3.33 (2.98-3.72)	2.74 (2.39-3.13)
Other beta-blockers (n=929)	206 (22.17)	2.08 (1.78-2.43)	1.93 (1.65-2.26)	1.69 (1.41-2.03)
Methyldopa (n= 515)	216 (41.94)	5.29 (4.44-6.31)	5.03 (4.21-6.01)	4.21 (3.38-5.23)
CCBs (n=86)	26 (30.23)	2.55 (1.63-3.99)	2.50 (1.60-3.89)	2.15 (1.26-3.67)
Perinatal mortality				
Unexposed (n=909 226)	6048 (0.67)	Reference	Reference	Reference
All beta-blockers (n=2459)	44 (1.79)	2.72 (2.02-3.67)	2.69 (1.98-3.65)	1.89 (1.25-2.84)
Labetalol only (n=1452)	30 (2.07)	3.15 (2.19-4.52)	3.24 (2.25-4.67)	2.08 (1.26-3.44)
Other beta-blockers (n=929)	13 (1.39)	2.12 (1.22-3.66)	1.92 (1.08-3.40)	1.72 (0.85-3.48)
Methyldopa (n= 515)	4 (0.78)	1.15 (0.43-3.07)	1.16 (0.43-3.12)	0.35 (0.05-2.50)
CCBs (n=86)	1 (1.16)	1.78 (0.25-12.57)	2.00 (0.28-14.83)	3.26 (0.45-23.77)

1

2

3

4 We found 86 pregnancies exposed to calcium channel blockers (table 3). These included 17

5 children born SGA, 18 preterm births and 1 perinatal death. We found an association between

6 exposure to calcium channel blockers and children born SGA in all models.

7 Additionally, we found an association between exposure to calcium channel blockers and

8 increased risk of preterm birth in all models. As with methyldopa, exposure to calcium channel

9 blockers during pregnancy was not found to be associated with perinatal mortality (table 3).

10 Analyses for exposure to ACE inhibitors were not performed since we identified only 48

11 pregnancies exposed to them.

1  
2  
3  
4 1 Post hoc we analysed the effect of exposure to all beta-blockers using a propensity score-  
5  
6 2 matched control group (Table 1) and found similar results to those of the primary analyses: SGA,  
7  
8 3 OR=1.93 (95% CI, 1.71–2.19); preterm birth, OR=2.40 (95% CI, 2.16–2.67); perinatal mortality,  
9  
10 4 OR=3.22 (95% CI, 2.15–4.82).  
11  
12  
13  
14

## 15 6 **DISCUSSION**

16  
17 7 In the present study, which we believe to be the largest of its kind to date, we found an association  
18  
19 8 between redeeming prescriptions of beta-blockers during pregnancy and being born SGA, preterm  
20  
21 9 birth, and perinatal mortality. In addition, we found an association between redeeming prescriptions  
22  
23 10 of methyldopa and calcium channel blockers, being born SGA, and preterm birth. Methyldopa and  
24  
25 11 calcium channel blockers were not found to be associated with perinatal mortality.  
26  
27

28 12 We found exposure to any beta-blocker to be associated with being born SGA. Our results are  
29  
30 13 in accordance with a recent study reporting increased risk of being born SGA among pregnancies  
31  
32 14 exposed to selective beta-blockers (OR=6.00; 95% CI, 1.06–33.87) and labetalol (OR=2.26; 95%  
33  
34 15 CI, 1.04–4.88).[9] Labetalol is generally considered safe for use during pregnancy.[1,8,21]  
35  
36  
37  
38  
39  
40

41 17 Exposure to beta-blockers was found to be associated with preterm birth. When stratifying for  
42  
43 18 different beta-blockers we found an increased risk of preterm birth after exposure to labetalol, and  
44  
45 19 all other beta-blockers, respectively.  
46

47 20 We found an association between exposure to beta-blockers and perinatal mortality. When  
48  
49 21 stratifying for different beta-blockers we found this association to be statistically significant for  
50  
51 22 exposure to labetalol and other beta-blockers. When adjusting our analysis for maternal co-  
52  
53 23 morbidity, co-medication, and smoking, only labetalol was found to be associated with perinatal  
54  
55 24 mortality.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Methyldopa is mainly used to treat chronic hypertension during pregnancy as first-line therapy.[1] Previous studies did not find any associations between methyldopa exposure and being born SGA or preterm birth.[1,3] Methyldopa has not been found to have effects on placental haemodynamics.[1] However, a recent case-control study reported an increased risk of being born SGA among pregnancies exposed to centrally acting adrenergic agents during the second and third trimesters[9]: OR=1.70 (95% CI, 1.00–2.89). We found that methyldopa exposure was associated with being born SGA and preterm birth. This could be due to indicative antihypertensive treatment with methyldopa in pregnant women with diabetes or pregnancy related diabetes. The prevalence of diabetes among methyldopa-exposed pregnancies was found to be higher: 11.1% compared with 3.9% among beta-blocker-exposed pregnancies. Increased risk of preterm birth was still seen after adjusting our analyses for additional confounding variables in model 2. We found no association between exposure to methyldopa and perinatal mortality. These findings are consistent with those of a previous study.[3]

Calcium channel blockers are considered to be safe during pregnancy.[3,22] We found that exposure to calcium channel blockers was associated with being born SGA and with preterm birth. The risk of being born SGA and preterm of birth remained after adjusting our analyses for additional confounding variables in model 2. We found no statistically significant association between calcium channel blocker exposure during pregnancy and perinatal mortality.

We chose to analyse two outcomes previously reported to be associated with beta-blocker exposure during pregnancy —SGA and preterm birth[1,10,23] — that have been associated with increased perinatal mortality in previous studies.[12,13] Therefore we investigated the risk of perinatal mortality among beta-blocker-exposed pregnancies. We compared risks associated with exposure to beta-blockers with exposure to methyldopa and calcium channel blockers to assess possible confounding by indication. Our analyses show a similar risk of being born SGA and an

1  
2  
3  
4 1 increased risk of preterm birth for all recommended agents during pregnancy. There are various  
5  
6 2 possible explanations for this finding. It is possible that the underlying indication for treatment,  
7  
8 3 maternal disease, is the true risk factor. Possible maternal diseases include hypertension, either  
9  
10 4 predated or complicating pregnancy. Accordingly, we were not able to rule out a potential effect of  
11  
12 5 maternal disease on perinatal outcomes.

13  
14  
15 6 We found an association between exposure to beta-blockers during pregnancy and perinatal  
16  
17 7 mortality. This association was not found for exposure to methyldopa and calcium channel  
18  
19 8 blockers, which might be due to the small number of cases.

20  
21  
22 9 We believe that the similar risks found for exposure to the various beta-blockers and SGA,  
23  
24 10 preterm birth, and perinatal mortality are a class effect. This seems to be true in spite of statistically  
25  
26 11 significant differences in the basic characteristics of women exposed to labetalol and those exposed  
27  
28 12 to other beta-blockers (table 2). After adjustments were made for these variables, we found  
29  
30 13 comparable risk profiles for labetalol-exposed pregnancies and pregnancies exposed to other beta-  
31  
32 14 blockers. Most beta-blockers are known to cross the placenta,[21,24] and effects on placental  
33  
34 15 haemodynamics have been observed in both human and animal studies. A mechanism has been  
35  
36 16 proposed of diminished placental blood flow due to the selective vasoconstriction of placental  
37  
38 17 vessels by beta-blockers without intrinsic sympathomimetic activity.[24] This effect on placental  
39  
40 18 haemodynamics could explain growth retardation of foetuses exposed to beta-blockers during  
41  
42 19 pregnancy and might result in children being born SGA and preterm.

43  
44  
45  
46 20 We defined exposure as redemption of at least two prescriptions between six months before  
47  
48 21 conception and the twentieth week of gestation. At least one of these prescriptions had to be  
49  
50 22 redeemed between conception and twentieth week of gestation. We believe that this model  
51  
52 23 increases the probability of identifying continuous use that extends into pregnancy.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 The rate of perinatal mortality in Denmark is low (table 3).[25] A large number of women  
2 exposed to beta-blockers, methyldopa, and calcium channel blockers are therefore needed to  
3 identify a possible risk increase associated with these outcomes. Our cohort comprises all births in  
4 Denmark between 1995 and 2008. This minimises confounding due to race, educational level, and  
5 other socio-economic factors. The national Danish registers cover the entire nation and are  
6 considered valid. As part of the national health care reimbursement scheme, Danish pharmacies are  
7 required by law to register all redeemed prescriptions. Approximately 97.5% of all redeemed  
8 prescriptions are registered in the Danish Prescription register.[16] Our study includes data on  
9 exposure to beta-blockers based on information on prescriptions paid for at the pharmacy, and not  
10 only prescribed by the physician, thereby increasing the probability of exposure. Furthermore, our  
11 study was not confounded by recall bias since information was recorded prospectively. The Danish  
12 Fertility Database contains more than 99% of all births during the study period.[14]

13 Limitations of our study include missing information on maternal weight and alcohol  
14 consumption. We were unable to adjust for treatment indication and severity of maternal disease.  
15 Given the study design, we were not able to address this issue further, nor were we able to rule out  
16 confounding by indication, the underlying maternal disease, as a possible explanation for our  
17 findings. Consequently we were unable to differentiate between a possible class effect of beta-  
18 blockers and the effect of the underlying maternal disease.

19 Unfortunately information on diagnoses of essential hypertension was not available, since  
20 these are known risk factors for our primary outcomes.

21 The prevalence of pre-eclampsia and eclampsia in the cohort is based on primary discharge  
22 diagnoses from hospital admissions. We did not use secondary diagnoses, since these in general are  
23 not validated. We estimated exposure from National Prescription Registry data, which contains  
24 information on all redeemed prescriptions.[16] Overestimation of exposure is therefore a

1 possibility, since we cannot adjust for a potential lack of compliance. However, in a study by  
2 Olesen et al. conducted in a cohort of pregnant Danish women in the county of North Jutland,[26]  
3 compliance with prescribed beta-blockers was estimated to be complete, strengthening the validity  
4 of our analyses. Furthermore, overestimation of exposure would bias the estimates towards unity.

5 There is a general consensus that labetalol is safer than other beta-blockers during pregnancy  
6 and this drug is rapidly becoming the first-line choice in conditions such as chronic hypertension  
7 during pregnancy.[21,23] We found an association between redeeming prescriptions for beta-  
8 blockers and being born SGA, preterm birth, and perinatal mortality. Risk profiles for pregnancies  
9 exposed to labetalol and to other beta-blockers were similar. ~~Our findings therefore suggest that  
10 future treatment of pregnant women with beta-blockers should be based primarily on the individual  
11 needs of the mother and not of the unborn child.~~ The increasing use and uncertainty of effects and  
12 possible side effects of treatment with beta-blockers during pregnancy call for further studies [to  
13 validate our findings.](#)

### 14 15 **Conflicts of interests**

16 The authors have no relevant conflict of interests.

### 17 18 **Funding**

19 The project was sponsored by the Capital Region of Copenhagen.

### 20 21 22 **REFERENCES**

- 23 1 Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996 Jul  
24 25;335(4):257-65.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 2 Magee LA, Ornstein MP, von DP. Fortnightly review: management of hypertension in  
2 pregnancy. *BMJ* 1999 May 15;318(7194):1332-6.
- 3 3 Afifi Y, Churchill D. Pharmacological treatment of hypertension in pregnancy. *Curr Pharm  
4 Des* 2003;9(21):1745-53.
- 5 4 Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during  
6 pregnancy. *Cochrane Database Syst Rev* 2003;(3):CD002863.
- 7 5 Modi S FAU - Lowder D, Lowder DM. Medications for migraine prophylaxis.(0002-838X  
8 (Print)).
- 9 6 Lyons KE FAU - Pahwa R, Pahwa R. Pharmacotherapy of essential tremor : an overview of  
10 existing and upcoming agents.(1172-7047 (Print)).
- 11 7 Sibai BM, Gonzalez AR, Mabie WC et al. comparison of labetalol plus hospitalization  
12 versus hospitalization alone in the management of preeclampsia remote from term. *Obstet  
13 Gynecol* 1987 Sep;70(3 Pt 1):323-7.
- 14 8 Magee LA, Elran E, Bull SB et al. Risks and benefits of beta-receptor blockers for  
15 pregnancy hypertension: overview of the randomized trials. *Eur J Obstet Gynecol Reprod  
16 Biol* 2000 Jan;88(1):15-26.
- 17 9 Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and  
18 the risk of major congenital malformations or small-for-gestational-age newborns. *Birth  
19 Defects Res B Dev Reprod Toxicol* 2010 Apr;89(2):147-54.
- 20 10 Lydakis C, Lip GY, Beevers M et al. Atenolol and foetal growth in pregnancies complicated  
21 by hypertension. *Am J Hypertens* 1999 Jun;12(6):541-7.

- 1  
2  
3  
4 11 Abalos E, Duley L, Steyn DW et al. Antihypertensive drug therapy for mild to moderate  
5  
6 2 hypertension during pregnancy. *Cochrane Database Syst Rev* 2007;(1):CD002252.  
7  
8  
9 3 12 Zeitlin J, El AM, Jarreau PH et al. Impact of foetal growth restriction on mortality and  
10  
11 4 morbidity in a very preterm birth cohort. *J Pediatr* 2010 Nov;157(5):733-9.  
12  
13  
14 5 13 Challis JR, Lye SJ, Gibb W et al. Understanding preterm labor. *Ann N Y Acad Sci* 2001  
15  
16 6 Sep;943:225-34.  
17  
18  
19 7 14 Knudsen LB. The Danish Fertility Database. *Dan Med Bull* 1998 Apr;45(2):221-5.  
20  
21  
22 8 15 Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A  
23  
24 9 valuable source of data for modern health sciences. *Dan Med Bull* 1999 Jun;46(3):263-8.  
25  
26  
27 10 16 Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. *Dan Med Bull* 1997  
28  
29 11 Sep;44(4):445-8.  
30  
31  
32 12 17 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments.  
33  
34 13 *Scand J Public Health* 2011 Jul;39(7 Suppl):103-5.  
35  
36  
37 14 18 Jensen VM, Rasmussen AW. Danish education registers. *Scand J Public Health* 2011  
38  
39 15 Jul;39(7 Suppl):91-4.  
40  
41  
42 16 19 Pedersen CB, Gotzsche H, Moller JO et al. The Danish Civil Registration System. A cohort  
43  
44 17 of eight million persons. *Dan Med Bull* 2006 Nov;53(4):441-9.  
45  
46  
47 18 20 Knudsen LB, Borlum KF. Monitoring perinatal mortality and perinatal care with a national  
48  
49 19 register: content and usage of the Danish Medical Birth Register. *Community Med* 1986  
50  
51 20 Feb;8(1):29-36.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 21 Karthikeyan VJ, Lip GY. Hypertension in pregnancy: pathophysiology and management  
2 strategies. *Curr Pharm Des* 2007;13(25):2567-79.
- 3 22 Magee LA, Schick B, Donnenfeld AE et al. The safety of calcium channel blockers in  
4 human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol* 1996  
5 Mar;174(3):823-8.
- 6 23 Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy.  
7 *Hypertension* 2008 Apr;51(4):960-9.
- 8 24 Lennestal R, Otterblad OP, Kallen B. Maternal use of antihypertensive drugs in early  
9 pregnancy and delivery outcome, notably the presence of congenital heart defects in the  
10 infants. *Eur J Clin Pharmacol* 2009 Jun;65(6):615-25.
- 11 25 World Health Organization. Levels & Trends in Child Mortality. Report 2011. Estimates  
12 Developed by the UN Inter-agency for Child Mortality Estimation. 2011.  
13 [http://www.who.int/child\\_adolescent\\_health/documents/child/childmortality\\_booklet\\_2011.](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf)  
14 [pdf](http://www.who.int/child_adolescent_health/documents/child/childmortality_booklet_2011.pdf), World Health Organization.  
15 Ref Type: Online Source
- 16 26 Olesen C, Sondergaard C, Thrane N et al. Do pregnant women report use of dispensed  
17 medications? *Epidemiology* 2001 Sep;12(5):497-501.